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Characterisation and use of Radiotracers in Studies of Inflammatory Tissue and Opioid Binding Sites. 
By Andrew John Lawrence. 
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The thesis is presented in two parts, part one concerns the synthesis and biodistribution of technetium-
porphyrin complexes: A series of compounds with the general formula TcO(Porhyrin)OAc and 
TcO(Phthalocyanine)OPh have been synthesised via a novel route. The starting material comprised 
NH 4 TcO 4 with acetic acid for the porphyrin and phenol for the phthalocyanine. The compounds have been 
characterised both qualitatively and quantitatively by infra-red, ultra-violet and mass spectrommetry. Thin 
layer chromatography (tic) and electrophoresis have also been employed to further analyse the complexes. 
Preliminary biodistribution studies have been performed in a model of inna~ed tissue. The results suggest 
that the labelled porphyrins are capable of imaging such tissue. One oflhe complexes was tested for an ability 
to accumulate in, and image tumours, however this proved unsuccessful. 
Part two concerns the properties of opioid agonist and antagonist binding: A number of opioid antagonists, 
reportedly selective for a single type of opioid receptor have been characterised in terms of binding profiles 
at all three opioid sites, namely].l -, 0 - and K-. The binding assays were performed in buffers of differing 
ionic strength. The compounds norbinaltorphimine, naltrindole and 16-methylcyprenorphine displayed a 
shift to higher affinity in more physiologically relevant conditions. The reasons for this are discussed in 
terms of possible intrinsic activity. The antagonists which pro~ed to be selective were further utilised to 
improve the uoderstanding of opioid binding sites. The unselective radioligand [3H1diprenorphine was 
employed to label opioid binding sites in both rat and guinea-pig brain. Inratbrain, the].l -binding component 
appeared non-homogeneous to both ].I -agonists and antagonists. These findings are discussed in terms of 
subtypes or different affinity states of the ].I -binding site which might exist under the assay conditions. 
Similarly in guinea-pig brain different binding site affinity states were observed beingparticulariy apparent 
at ].I - and 0 -sites by comparison of agonist (DAGOL, DPDPE) and antagonist (croP, naltrindole) binding. 
The K -site population appeared to be more homogeneous both by competition assay and also in saturation 
assays. Possible K -receptor heterogeneity was further studied in the guinea-pig ileum myenteric plexus 
longitudinal muscle preparation. Four K-agonists, namely ethylketocycJazocine, U69593, lCI 204448 and 
dynorphin (1-13) were compared. Schild analysis was performed using naloxone as an antagonist and the 
results suggest that dynorphin (1-13) may be acting at a different receptor to the other compounds. 
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PART ONE 
The 
Synthesis and Biodistribution 
of Technetium-Porphyrin 
Complexes 
INTRODUCTION. 
1.1 Properties of Technetium-99. 
Technetium is a 2nd. row transition element in group VIIa of the Periodic 
Table, situated in between manganese and rhenium. 
Technetium and rhenium are chemically very similar and differ 
considerably from manganese, despite similarities in the stoichiometries of 
a few compounds (such as the series Mn04 -, Tc04 -, Re04 - and the metal 
carbonyls) [11 The most stable and characteristic oxidation state for 
manganese is the II state, for which the chemistry is mainly that of the 
high-spin Mn2+ cation. Technetium and rhenium have little cationic 
chemistry, form few compounds in the II oxidation state, and have extensive 
chemistry in the IV and especially V states. The Tc04 - and Re04 - ions are 
much less oxidising than Mn04 -. A characteristic of ReIII in its halides 
is the formation of metal-metal bonds, technetium also does this to some 
extent whereas Mn forms no such compounds at all. 
Technetium has the electronic configuration I s22s2p63s2p6d10 4s2p6d5 5s2 and 
as previously mentioned can exist in various oxidation states (-I to +VID 
which represent degrees of electron density:-
low oxidation state - high electron density 
high oxidation state -low electron density 
To stabilise a low oxidation state use a 'soft' ligand capable of spreading 
the electron charge for example phosphines, cyanides, isonitriles 
(n-acid ligands). Conversely to stabilise a high oxidation state use a 'hard' 
1 
ligand possessing lone pair electrons or a formal negative charge such as 
0, cr. 
1.2 Tc-99m Radiopharmaceuticals. 
Tc-99m is the main radionuclide of choice for diagnostic nuclear medicine 
[2] due to the following 5 properties:-
1. It has a half-life of 6.02 hours which permits diagnosis over a reasonable 
period of time without administering an unnecessarily high radiation 
dose to the patient. 
2. The photon energy peak of I 42KeV is suited to today's I-cameras 
which operate best between 100-200KeV. 
3. Generator technology means that Tc-99m is readily available in a 
sterile solution and in a chemically useful state. 
4. Technetium has several oxidation states and stereochemistries available 
giving a broad and varied co-ordination chemistry. 
5. There is no cxor S emission and radiation dose from theTc-99 daughter 
is minimal. 
From the above it is evident that technetium radiopharmaceuticals can 
contain the technetium in various oxidation states. Some examples are 
listed below: 
2 
1. DMSA: dimercaptosuccinic acid [31 
Figure 1. 
HS SH 
\ / 
CH-CH 
/ \ 
H02C C0 2H 
At low pH: TcIV renal imaging agent. 
At high pH: TcV tumour imaging agent. 
2. DTPA: diethyltriamine pentaacetic acid [41 
Figure'2. At low pH: TcV and TcIIl. 
At pH6: TcIV renal function agent. 
These radiopharmaceuticals occur in the form of 'kits' where Tc04 - in 
a sterile saline solution is introduced into a freeze-dried sample of ligand 
and reducing agent (usually SnID whereupon a water soluble Tc complex 
is formed ready for injection. Tc-99m in the form of Tc04- is readily 
available from generators based on the decay of 99Mo:_ 
3 
s-
______ ~) 99mTc 
67 hours 
y 6.02 hours 
99Ru ... ( ------
2.1 x 10 5 years 
Figure 3. 
The generator is basically a column of ammonium molybdate in powder 
form which, when eluted with saline, gives an isotonic sterile solution of 
ammonium pertechnetate in accordance with the above decay scheme. 
An example of a Tc-99m labelled porphyrin as a radiopharmaceutical 
has been reported by Zanelli and co-workers [5], who have shown that 
[99mTc]Tc04 - reacts with sulphonated tetraphenylporphyrins in citrate 
buffer with SnII as a reducing agent. This formulation accumulates the 
radioactivity in sites of inflamed tissue e.g. abscesses, but not in tumours. 
However, it has proven impossible to synthesise the longer lived Tc-99 
complexes by this method. 
1.3 Porphyrin Chemistry 
1.3.1 Introduction 
Porphyrins are of great interest as ligands in biological systems due to the 
unique nature of the coordination chemistry of these materials [6J. 
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Changes or modification of general porphyrin metabolism are associated 
with cancer, drug metabolism and specific disease syndromes such as 
porphyria [7]. [The condition of porphyria results from a metabolic disorder 
in which porphyrin is retained in the tissue; it is always associated with 
an excess of porphyrin in the blood (porphyrinaemia) and in the urine 
(porphyrinuria). The symptoms may be precipitated by certain drugs e.g. 
sulphonamides. There are various forms of porphyria some of which are 
genetically determined for example congenital porphyria which is a rare, 
genetic, erythropoietic porphyria in which there is a defect of haem synthesis 
in erythrocytes.] Thus, the biological functions of metalloporphyrins have 
a great deal of importance. Most of the research into metalloporphyrins 
not only stems from interest in the biological systems to which they are 
related, but also from the search for new anti-cancer drugs and tumour 
localising agents [81 
Understanding of the porphyrin system has advanced appreciably in the 
last two decades [9], to the extent that almost every metal in the periodic 
table has been coordinated to a porphyrin [J 01 
1.3.2 Synthesis 
There are four main synthetic routes available for the synthesis of 
metalloporphyrin complexes:-
1. Reaction of a porphyrin with a metallic salt (acetate, halide, oxide) 
in an acidic or basic medium [J I], for example 
Copper acetate + porphyrin -----> Cu(porph) 
acetic acid 
5 
2. Supplying the metal in the form of carbonyls, carbonyl halides or other 
organometallic compounds [I21 for example 
-----) <Porph)TdCO)3 
decalin 
3. The use of an acetylated complex as a source of metal U31 
4. Reaction in a medium of high dielectric constant such as phenol, 
N,N-DMF U4], for example 
FeCl2 + Porphyrin -----> Fe<Porph)Cl 
DMF 
The major problem in the traditional metalloporphyrin syntheses is the 
difficulty in dissolving both the free porphyrin and the metallic salt 
simultaneously into the same solution under reactive conditions Ull This 
is due to the fact that suitable solvents for the porphyrins in their 
un-ionised forms are generally poor solvents for simple metallic ions and 
vice versa. The solubility problem was overcome by using high dielectric 
solvents which are capable of dissolving both the free porphyrin and the 
metallic salt. It is general, rapid, convenient, usually gives high yields and 
requires no special reagents. This method was developed by Adler [141 for 
the preparation of a number of previously unknown metalloporphyrins 
such as Hf, Si, lx, W porphyrins. 
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1.3.3 Group YHa 
Since technetium is in group YHa it would be prudent to study known 
methods for the synthesis of other group YHa porphyrin complexes before 
undertaking any major experimental work. 
Buchler and Rohbock [15] reported the ability to make Re porphyrins by 
the reaction of Re20 r with octaethylporphyrin (H20EP) in phenol. This 
yields two products. Reo[OEP](OPh) and the dimeric [ReO(OEP)]20. 
Boucher [16] described the synthesis of a Manganese III porphyrin by 
refluxing a mixture of the divalent metal acetate and porphyrin in glacial 
acetic acid. 
Porphyrin complexes of technetium in high oxidation states have not 
previously been prepared although Tsutsui has synthesised from Tc2(CO),o 
and the porphyrin. TC(CO)3<HPorph) and also a dimeric species 
[Porph]ITc!CO)3]2 which both have the technetium in the +1 oxidation state 
[] 71 Figure 4 shows that these complexes have the metal co-ordinated 
to only three of the N atoms of the porphyrin ring and hence the metal 
is out of the ring plane. 
Figure 4a. (HPorph)TcCC0l3• 
L... _______________ _ 
NB. Ring substitution 
and conjugation 
omitted for clarity. 
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These are both prepared by refluxing TC2(CO)10 and the porphyrin in decalin 
and the dimeric complex is obtained by heating two equivalents of the 
monomer which disproportionates to the dimer and free porphyrin. 
1.3.4 Spectroscopy. 
The study of porphyrins and metalloporphyrins is based mainly on 
qualitative and quantitative changes in electronic/optical spectra, since from 
the early days of study it was known that the parent molecule, or 
free-base, with two hydrogens in the centre, has a four-banded absorption 
spectrum distinctly different from the two-banded visible spectrum shown 
by most metal complexes and by the acid dication (figures 5 and 6) [18J. 
Therefore one can distinguish a free base type and a metal type spectrum. 
This difference arises from the fact that the two free-base hydrogens in 
the centre strongly reduce the conjugated ring symmetry from D4h to D 2h, 
however within the class of metalloporphyrins changes in optical absorption 
are dependent on the ligands trans to each other in the centre of the ring 
[19J. All metalloporphyrins show the following characteristic spectra:-
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1. Q bands: Two visible bands are seen between 500 and 600nm. The 
lower energy band <sometimes called IX) is the electronic origin Q(O,o> 
of the lowest energy excitedsinglet state. The higher energy band 
<Sometimes called B) includes a mode of vibrational excitation and is 
denoted QO,O> - it is actually a merging of several different vibrations. 
It was originally identified as a vibration on the basis of the relative 
constant energy gap between QU,O> and Q(O,O) [201 The QO,O> band 
generally has a molar extinction coefficient in the narrow range of 
1.2-2 xlctM-1cm-1 [I 11 
2. B bands: An exceedingly intense band <sometimes called the Soret band) 
appears between 380 and 420nm. It is the origin B(O,Q) of the second 
excited singlet state and has molar extinction generally from 
2-4xI05M-1cm-1• 
3. N,L,M bands: To the blue of the Soret band,meta1loporphyrinsgenerally 
show a weaker N band at ~ 325nm and an M band at ~ 215nm [21]. 
Between these they often show a weaker L band usually appearing as 
a shoulder on either the N or M band. 
All of these bands are interpreted as (TT,TT*) in ongm and the Q,B 
nomenclature was originally given by Platt [201 B implies a strongly allowed 
excited state and Q a quasi-allowed one. Later the N,L bands were identified 
in solution spectra [2 G whereas the M band is only seen in vapour [221 
These are features of regular metalloporphyrins however the group YHa 
tend to form irregular metalloporphyrin complexes known as 
hyperporphyrins because they show prominent extra absorption bands 
U >1000M-1cm-1) in the region }..>320nm where normal metalloporphyrins 
show only Q,B and N (TT,TT*) bands. 
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Figure 5. 
A 
400 Alnm 800 
Absorbance (A) is in arbitrary units. 
Figure 5 shows a magnification of the visible spectrum of H2- TPP. This 
four banded spectrum is typical of free base porphyrins. 
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Figure 6. 
200 A/nm 800 
Absorbance (A) is in arbitrary units. 
Figure 6. The electronic spectrum of tIrOEp2+ showing the typically two-
banded visible region as compared to the four-banded one of a free base 
porphyrin. 
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They are further classified into d-type hyperporphyrins which are found 
with transition metals in configurations of dm, 1 ~ m ~ 6, that have relatively 
stable lower oxidation states. These extra bands are attributed with somewhat 
uncertainty to charge transfer transitions. Another name for them is 
alloporphyrins since unlike the usual metalloporphyrins which are red to 
orange in solution, alloporphyrins are characteristically olive-green or 
brown [23J. Calvin and co-workers were the first to systematically study 
the optical spectra of the archetype d-type hyperporphyrin complex of 
Mn<IIl) [24 J. These studies also included the oxidised and reduced porphyrins, 
Mn<IV), Mn<II). The spectra of (TPP)Mn<IIDCl has absorptions as follows:-
2 bands between 800-650nm. 
2 bands in the normal metalloporphyrin region [Q(O,O> and 
QO,O)] ie 500-600nm. 
1 band at ~ 450nm. 
1 band at ~ 350nm. 
The intensity ratio in between the latter two bands is quite variable depending 
on the metal and substituents on the porphyrin. 
The porphyrin complexes of CumD, Mn<IIl), MO<V), WM and Re(V) all show 
rather similar hyper absorption spectra and fit the pattern defined as 
d-type hyper quite well. 
1.3.5 Medical Uses of Porphyrins. 
Free base porphyrins are known to accumulate in tumours but the evidence 
for metalloporphyrins is not clear [25J. lllIn labelled porphyrins are known 
to accumulate in tumours but for metalloporphyrins there is little or no 
evidence of preferential tumour uptake [261 
12 
As already mentioned in § 1.1 Zanelli and co-workers [5] have shown a 
Tc-99m labelled porphyrin to be a useful imaging agent for sites of 
inflammation such as in Crohn's disease. Hence there is plenty of scope 
for biological studies on novel technetoporphyrin complexes. 
1.3.6 Porphyrins Chosen to Study. 
The study undertaken was based mainly on three porphyrin molecules:-
a) 1.2,3,4,5,6,7,8,-octaethylporphyrin (H20EP>. 
This was first synthesised by Fischer in 1928 [27], and has the structure 
shown in figure 7. 
Figure 7: H20EP 
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This was chosen for 2 main reasons:-
D It is structurally similar to the naturally occurring protoporphyrin IX 
<PPIX) which is the prosthetic group in the oxygen transport and storage 
pigments haemoglobin and myoglobin [28J. 
Figure 8: The structure of PPIX 
iD It is favoured for optical study since all porphyrins with eight alkyl 
groups on the exo pyrrole positions have essentially the same optical 
properties [29J. High symmetry is a prerequisite for an easy 
interpretation of spectra and a reduction of isomers produced in a model 
reaction of potential biochemical interest. 
b) (X,8 ,1,6 -tetraphenylporphyrin <H2TPP). 
The structure of H2 TPP is shown in figure 9. 
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Figure 9: H2 TPP 
This too is favoured for optical study since it has very characteristic 
absorption spectra and substitution of the phenyl rings in the para position 
have negligible or small effects on the absorption spectra. 
c) (X,9,Y,6 -tetraphenylporphyrin disulphonate (H2 TPPS2). 
This was chosen as a water soluble derivative of H2 TPP which would be 
better for a potential injectable preparation. 
Also chosen to study was the porphyrin-like ring system of phthalocyanine 
(tetrazatetrabenz-porphyrinl. 
15 
NH 
N 
~\ 
Figure 10: H2 TPPS 2 
1.4 Phthalocyanine Chemistry. 
Phtha10cyanine is a tetrazatetrabenz-porphyrin and figure 11 shows its 
structural similarity with the aforementioned porphyrins. 
Figure 11: Phthalocyanine (PC) 
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The extremely high thermal stability, fastness to light, inertness to acids 
and alkalis, insolubility in most solvents, high dyeing power, purity and 
colour intensity has ensured the wide application of phthalocyanines in 
the paint, textile and paper industries as well as in chemical fibre and plastic 
dyeing processes [30]. 
1.4.2 Synthesis. 
A specific feature of synthesising phthalocyanine complexes is that they 
are seldom obtained from an available phthalocyanine ligand. More often 
the complex is formed from molecular fragments of phthalocyanine, namely 
phthalonitrile, phthalimide, phthalic anhydride and other derivatives of 
o-phthalic acid in the presence of a metal ion source - chlorides, acetates, 
oxides of metals. For example [99Tc] Tetrasulphophthalocyanine has been 
prepared by the condensation of 3-sulphophthalic acid and pertechnetate 
in the presence of a reducing agent [311 The [99mTc] analogue of this 
complex has also been synthesised by the same method and studied for 
tumour uptake properties [321 
Another method of obtaining metallophthalocyanine complexes is by recoil 
implantation, for example technetium and rhenium phthalocyanines have 
been synthesised by recoil implantation of isotopes generated by (d,xn) 
reactions induced by 40MeV deuteron irradiation with copper 
phthalocyanine [331 
1.4.3 Spectral Properties. 
Like metalloporphyrins, metallophthalocyanines are best studied via 
characteristic optical spectra. Phthalocyanine complexes have a broadened 
17 
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Soret (380-420nm) band due to underlying (n,n*) transitions and they also 
may have an extra band known as a C band at lower wavelengths (higher 
energy) than the N or L bands (250-350nm). 
The optical absorption spectra of phthalocyanines as a function of the 
central metal have not had so much detailed study as the spectra of the 
porphyrins. In general metallo complexes that are regular as porphyrins 
are also regular as phthalocyanines, that is their visible and near UV spectra 
are principally (n,n*) in origin, with perhaps bridge (n,n*) contribution in 
the Soret (~350nm) region. Extra visible absorption bands are found in 
some of the same metallophthalocyanines, such as MnGm, as shown in 
porphyrins. 
1.5 The Aim of the Project. 
The purpose of the project was to synthesise, starting from NH4 Tc04, novel 
[9 9Tc] technetoporphyrin complexes with the technetium in a high oxidation 
state as opposed to those in the +1 state reported by Tsutsui [1 71 An advantage 
being the higher stability of high oxidation state technetium complexes as 
opposed to lower oxidation states. Most Tc-radiopharmaceuticals have the 
technetium in the V state. These complexes could then be characterised 
and determined unambiguously before the synthesis was repeated using 
[99mTc] to allow biological studies to be carried out. 
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EXPERIMENTAL. 
2.1 Materials. 
Octaethylporphyrin (OEPH2) and phthalocyanine (PO were purchasedfrom 
Aldrich and used without further purification. Tetraphenylporphyrin 
(H2 TPP) was purchased from Sigma and used without further purification. 
Tetraphenylporphyrin disulphonate (H2 TPPS2) was obtained as a gift from 
Dr. Zanelli at CRC. Northwick Park Hospital (Harrow). Solid [99Tc] 
NH4Tc04 was obtained from Amersham International and recrystallised 
prior to use. [99mTc] NH4 Tc04 was obtained from Amertec II generators 
kindly donated by Leicester Royal Infirmary's Radiopharmacy Dept. All 
other reagents were of laboratory grade from various manufacturers. 
Thin layer chromatography plates (0.2mmx20cm) of Kieselgel 60 were 
purchased from Merck. Electronic spectra were measured on a 
Shimadzu UV -160 spectrophotometer while vibrational spectra were 
obtained using a Perkin-Elmer 257 spectrophotometer with the material 
dispersed in a KBr disc. F AB mass spectra were observed using a 
Varian-Mat 731 operating at lOkV and employing a matrix of 
thioglyceroll erythri toll di thioerythrei tol. 
Electrophoresis experiments were carried out using a Shandon Southern 
602 chamber with a Volkam 400/100 power pack paper in phosphate 
buffer pH7. ran on 25cm strips of Whatman 3MM paper and the tests 
allowed to proceed for 2 hours at 300V. 
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2.2 Methods. 
2.2.1 Porphyrin Complexes. 
The complex octaethylporphyrinato(oxo)technetium(V)acetate was 
synthesised by the following method. This may be used to prepare a number 
of analogous complexes containing different porphyrins. [99TcJ NH4Tc04 
(8mg, 4.42xlO-5 moles) and OEPH2 (23.64mg, 4.42xlO-5 moles) were added 
to glacial acetic acid (50mD under a nitrogen atmosphere and the mixture 
refluxed for four hours. After cooling, the solution was reduced in volume 
to ca. 5ml and the mixture was chromatographed using CHzC1z as the 
eluting solvent. 
The product appeared as a green band separate from unreacted OEPH2 
and protonated OEPH/+. The complex was isolated from the Kieselgel 
60 using ethanol. Evaporation of the ethanolic solution gave a green solid 
which can be recrystaIlised from a acetic acid! diethyl ether mixture with 
a yield ca. 40%. 
2.2.2 Phthalocyanine Complexes. 
An analogous [99Tc1 technetiumphthalocyanine complex to the previously 
mentioned porphyrin complexes is preparable by the following route . 
. [99Tc1 NH4Tc04 (8.3mg, 4.6xlO-5 moles) and PC (23.6mg, 4.6xlO-5 moles) 
were added to phenol (50mH under a nitrogen atmosphere and the mixture 
refluxed for four hours. Following this the phenol was evaporated under 
gentle heating with nitrogen and the resulting solid was redissolved in an 
ethanol! water mixture. This allowed isolation of the product to be achieved 
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using a Cl8 Sep-Pak (reverse phase) in the normal manner. The product 
was isolated out of the Sep-Pak with ethanol in the form of a blue-green 
solution. 
2.2.3 Redox Reactions. 
Redox reactions were carried out on all of the complexes synthesised in 
the following manner. Firstly a drop of pyridine was added to ca. 5ml 
of an ethanolic solution of the complex under study. and the solution stirred 
for 30 minutes. Following this the electronic spectra was measured and 
then 5mg of sodium dithionite (reducing agent) was added to the solution 
and stirred for a further 30 minutes. Then the solution had the sodium 
dithionite filtered out. the electronic spectrum was measured again. 
Also ran in parallel was purely a reduction of the complex solution by 
5mg of sodium dithionite in the same manner as above. 
These experiments were performed each time a particular batch of complex 
was made. with varying concentrations of complex. and can be quantified 
by studying peak height ratios. 
Each time the experiments were performed a series of dilutions were made 
from 0.1 pyridine: 1 complex up to 50:1. and the results quantified in 
terms of peak height ratios. 
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2.2.4 Spectral Measurements. 
2.2.4.1 Vibrational Spectra. 
The vibrational spectra were measured with the material dispersed in a 
KBr disc using a Perkin-Elmer 257 spectrophotometer on a purely 
qualitative basis to observe any additional peaks in the complexes compared 
to free-base porphyrin. 
2.2.4.2 Mass Spectra. 
Mass spectra were carried out by a technician in the mass spectrometry 
department at Northwick Park Hospital using a Varian-Mat 731 operating 
at lOkV. 
2.2.4.3 Electronic Spectra. 
Electronic spectra were measured in ethanolic solutions using a Shimadzu 
UV -160. The solutions were obtained by scraping off the isolated band 
from the silica TLC plates and extracting the complex out of the silica 
with ethanol. Unless stated spectra are qualitative without calculated 
extinction coefficients, however quantification can be made in terms of 
peak height ratios. For each complex, peak height ratios remained constant 
on varying concentrations. Following the redox reactions the new peak 
height ratios also remained constant over a dilution range of up to 50:1. 
Absorbance below 300nm on spectra involving pyridine should be ignored 
due to possible interference caused by pyridine absorption and also 
instrumental error in lamp change over. The spectra reproduced in this 
report are photoenlargements of the originals obtained from the Shimadzu 
UV-160. 
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2.3 Biological Evaluation. 
All of the animal work was carried out at CRC/MRC Northwick Park 
Hospital under the direct supervision of Dr. G. D. Zanelli who is responsible 
for all of the biodistribution data. 
The biological models used were of two types:-
a) Male adult Sprague-Dawley rats with one abscessed rear leg - generated 
by turpentine influx. 
b) Mice containing the CBA carcinoma NT. 
These two models were chosen on the grounds already mentioned in ~ 1.3.5 
(references [5] and [25]). 
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3. RESULTS AND DISCUSSION. 
3.1 Octaethylporphyrin Studies. 
Re20 7 has been shown to react with H20EP in phenol to give two complexes 
ReO(OEP)OPh and [ReO(OEP)]20 [I5J. A similar reaction with NH4 Tc04 
gave only minute yields of a possibly analogous green complex, even after 
prolonged refluxing. The visible spectrum has a broad absorbance at 57 5nm 
with a shoulder on the main Soret band (364nml at 456nm. Due to the 
poor yield further characterisation of this species proved impossible. 
However using glacial acetic acid as the solvent the reaction proceeds 
smoothly. A green product is obtained in high yield which is soluble in 
dichloromethane, benzene and appears neutral by electrophoresis. The 
electronic spectrum of the complex, measured using ethanol as the solvent, 
is reproduced in figure 12. It has two sharp absorptions at 49 9nm and 
470nm, with a broad absorption at 617nm. This compares with the four 
banded visible spectrum of H20EP (622, 569, 532, 498nml and the two 
banded one of H40Ep 2+ (569, 533nml and is a typical metalloporphyrin 
spectrum. The Soret band of the complex is split in two with absorptions 
at 391 and 344nm, while those for the non-metallated porphyrins are 
at 404 and 405nm respectively. 
The vibrational spectrum has absorptions typical of a metalloporphyrin 
and an additional absorption at 1604cm-1• This latter vibration is similar 
to those observed in other octaethylporphyrinatometalacetates [34J. Two 
absorptions at 962cm-1 and 918cm-1 are in the region typical of v (Tc=Ol 
[35] but an absolute assignment is impossible. ReO(OEP)F has v (Re=Ol at 
953cm-1 [36] and the 962cm-1 absorption seems more probable. 
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Figure 12. 
The electronic spectrum of the complex (OEP)TcO(OAcl. 
2.5 ....-_________________ --, 
A 
o L-____________________ ~ 
200 >-/nm 800 
>-ma/nm ~ Imol-ldm3cm-1 >-ma/nm ! Imorldm3cm-1 
617 4.4X!03 382 1.6xl04 
499 6.4X!03 344 1.8X!04 
470 6.9x!03 
These values are in accordance with previously reported rhenium complexes 
of OEP [341 
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Figure 13: FAS+ mass spectrum of the(OEP} le O/OAe)eomplex. 
-------------------------------------------------------------------
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Figure 14. 
A 
200 Alnm 800 
Absorbance (A) is in arbitrary units. 
Figure 14 shows the effect on the UV Ivisible spectrum of the complex 
(OEP)TcO(OAd caused by the addition of pyridine. Extinction coefficients 
are unknown. however dilution up to 1:50 causes no change in the ratio 
of peak heights. 
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Figure 15. 
A 
200 >'/nm 800 
Absorbance (A) is in arbitrary units. 
Figure 15 shows the change in the UV Ivisible spectrum of (OEP)TcO(OAd 
caused by the addition of pyridine, followed by sodium dithionite reduction. 
Dilution up to 1:50 causes no change in the ratios of the peak heights. 
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Figure 16: FAB+ mass spectrum of the product arising from 
the addition of pyridine and subsequent reduction 
of the(OEP} Tc O{OAc) complex. 
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The F AB+ mass spectrum of the complex is reproduced in figure 13 and 
shows the major peak to be at m/z of 647, this corresponds to ITcO(OEPW. 
In F AB+ mass spectrometry a parent ion [M+HJ+ is normally observed but 
in those technetium species with labile ligands trans to an oxo the major 
ion is usually [M-Lt where L is the trans ligand. Additionally the matrix 
employed is an acidic one and loss of acetic acid by protonation to give 
[M-LJ~ could occur. This appears to be the case for octaethylporphyrinato-
(oxo)technetium (V) acetate. This complex may be used to synthesise a range 
of new technetium porphyrins and figure 14 shows the reaction of 
(Q~p)Tc..o(bAc:)with pyridine. The change in the visible spectrum was 
originally presumed to be indicative of ligand exchange of the trans acetate 
ligand. Further addition of sodium dithionite, (a reducing agent), caused 
additional changes to the visible spectrum figure 15, and an F AB+ mass 
spectrum (figure 16) shows this to be a reduction of the technetium oxo 
core to yield technetium (IV) or technetium (Ill) porphyrin. Furthermore, 
the mass spectrum shows no evidence of ligand exchange between the acetate 
and pyridine and from this one would conclude that the change in visible 
spectrum may be due to solvation by pyridine or that the complex in solid 
state is different to that in solution of pyridine. The reduction of the 
technetium oxo core is shown by the emergence of the peak at m/z 631 
which is approximately 40% of the peak at m/z 647 and corresponds to 
TdOEW. This peak is seen in the spectrum of (of:PHc.cCoAt) however 
it is less than 10% of the parent ion at m/z 647. 
Therefore despite the fact that ligand exchange was not achieved, a reduction 
of the Tc=O core to yield different complexes was achieved. 
Animal studies were performed on the complex (O€P)TcOCdlc) however 
solubility proved to be a problem due to the lipophilic nature of the complex. 
This was partially overcome by addition of a small amount of Tween 80 
to act as a solubiliser. 
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The tests were carried out by Dr. G.D. Zanelli as follows:-
1 ml of the complex in ethanol was diluted to 10ml with sterile saline to 
give approximately 100~ Ci/ml. Each of six male adult Sprague-Dawley 
rats with abscess in right hind leg were injected I.V. in the tail with Iml 
and scanned on the 'Y -camera firstly in a dynamic mode, i.e. 1 minute 
frames for 30 minutes, and secondly in a static manner 45 minutes post 
injection. 
The rats were then sacrificed at varying time intervals post injection from 
24 minutes to 18 hours by cardiac puncture and removal of ca. 15.5ml 
of blood (average blood volume of these rats). Following sacrifice various 
organs were removed and counted to give separate organ values including 
liver, spleen, lungs, kidneys, heart, right leg, left leg and finally carcass. 
The legs were cut at mid-femur and counted in a bulk counter. 
The standard was designated as 0.5% of the injected dose which gave an 
average of 13926 cpm and hence the activity injected is equivalent to 
2,765,200 cpm. Results are shown in table 1, expressed as % of injected 
dose and also % whole body (cpm tissue/cpm total>. 
As can be seen from the table the activity tends to accumulate in the liver 
and lungs due to the high lipophilicity, however the right leg can be seen 
well on density boost (see photographs in figure 17). 
Table 2 shows the ratio of right leg (abscess) : left leg (normal> for the various 
rats. 
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Table 1. 
24min 
Blood 0.66 
0.61 
Liver 42.50 
38.90 
Kidneys 0.64 
0.58 
Lungs 39.01 
35.74 
Heart 0.28 
0.25 
Rt. leg 0.64 
0.59 
L. leg 0.52 
0.48 
Carcass 13.54 
12.38 
Spleen 2.74 
2.50 
% whole body. 
% injected dose. 
Time of Sacrifice Post Injection. 
I hr. 4hrs. 6hrs. 8hrs. 18hrs. 
0.24 0.77 0.2 0.36 0.41 
0.18 0.67 0.19 0.32 0.46 
29.77 51.37 54.20 65.20 5'i.60 
21.60 ' 44.57 52.20 56.90 45.05 
0.34 0.98 1.21 1.29 1.01 
0.25 0.85 1.17 1.13 1.12 
23.03 21.82 17.02 10.20 11.96 
16.71 18.94 16.39 8.91 13.28 
0.06 0.41 0.27 0.16 0.16 
0.04 0.36 0.26 0.14 0.175 
0.74 2.40 1.61 1.70 2.14 
0.53 2.08 1.55 1.48 2.37 
0.24 1.03 0.57 0.74 1.10 
0.17 0.89 0.54 0.64 1.22 
41.22 13.21 16.26 15.50 15.79 
29.90 11.47 15.66 13.54 17.50 
4.36 7.99 8.65 4.89 8.84 
3.16 6.93 8.33 4.25 9.81 
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Table 2. 
Time post injection. Ratio of Rt. leg : Left leg. 
24 min. 1.24 
1 hour. 3.12 
4 hours. 2.33 
6 hours. 2.84 
8 hours 2.30 
18 hours. 1.95 
As can be seen from the two tables the activity in the right leg with the 
abscess peaks between 1-4 hours and there is approximately 2~ times the 
activity in the abscessed leg compared to the normal leg. 
Figure 17 shows a series of photographs from both the dynamic and static 
scans of rats with an abscess in the right leg. 
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Figure 17.1: 
A. Dynamic scan, 1 minute, normal. 
A. Liver. 
B. Lungs. 
B. Dynamic scan, 1 minute, density boost. 
A. Head. 
B. Right hind leg (abscess). 
C. Tail. 
C. Dynamic scan, 5 minutes, normal. 
A. Liver. 
B. Lungs. 
D. Dynamic scan, 5 minutes, density boost. 
A. Head. 
B. Right hind leg (abscess). 
C. Tail. 
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Figure 17.2: 
A. Dynamic sca n, 10 minu tes , normal. 
A. Liver. 
B. Lungs. 
B. Dynamic scan, 10 minutes, density boost. 
A. Head. 
B. Rig ht hind leg (abs cess). 
C. Toi l. 
C. Dynamic scan, 17 minutes, normal. 
A. Liver. 
B. Lungs. 
D. Dynamic scan, 17 minutes, density boost. 
A. Head. 
B. Right hind leg ( abscess). 
C. Toil. 
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Figure 17.3: 
A. Dynamic scan, 29 minu les, norma l. 
A. Liver. 
B. Lungs. 
B. Dynamic scan, 29 minutes, dens ity boast. 
A. Head. 
B. Right hind leg (abscess) . 
C. Toi l. 
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Figure 17.4: 
A. Sta tic , 30 minutes, density boost. 
A. Head. 
B. Right hind leg (abscess) . 
C. Ta il. 
B. Stalic, 1 hour, density boost. 
A. Head . 
B. Rig ht hind leg (abscess). 
C. Ta i l. 
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3.2 ex ,B ,'Y ,cS - Tetraphenylporphyrin Studies. 
Substituting H2- TPP for H2-OEP, an analogous green complex can be 
prepared indicating that this is probably a general route for labelling 
porphyrins with 99-Tc. The electronic spectrum of the complex is 
reproduced in figure 18 showing two sharp absorptions at 596 and 55 6nm 
with a shoulder at 467nm. The Soret band occurs at 425nm in comparison 
with that of H2 - TPP which is found at 415nm (figure 19), 
The visible spectrum of the complex compares with that of the free base 
porphyrin which is four banded (646, 591, 549 and 514nm) and the 
protonated porphyrin H4-TPP 2+ which is two banded (591 and 549nm). 
These variations follow the same trend as in the OEP studies. 
Figures 20, 21 and 22 reproduce the electronic spectra from the redox 
reactions of the Tc-TPP complex. Figure 20 shows that on addition of 
pyridine the shoulder at 467nm begins to disappear and a new peak at 
403nm emerges in the form of a shoulder on the main Soret band. The 
further addition of reducing agent causes a total loss of the shoulder at 
467nm (figure 21) which can be concluded to be caused by pyridine since 
it is present in figure 22 which is a control reaction of the Tc-TPP complex 
with sodium dithionite (reducing agent). However, interestingly the peak 
around 400nm is far more pronounced rather than being in the form of 
a shoulder as compared to figures 20 and 21. 
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Figure 18 
A 
200 Alnm 800 
Absorbance (A) is in arbitrary units. 
Figure 18 shows the electronic spectrum of the Tc-TPP complex. Extinction 
coefficients are unknown although the ratio of peak heights does not vary· 
with concentration. 
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Figure 19. 
A 
---- -
200 )../nm 800 
Absorbance (A) is in arbitrary units. 
Figure 19 shows the electronic spectrum of H2- TPP indicating the intense 
absorption of the Soret (E) band at 415nm. 
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Figure 20. 
A 
200 A/nm 800 
Absorbance (A) is in arbitrary units. 
Figure 20 shows the effect of the addition of pyridine on the electronic 
spectrum of the Tc-TPP complex. Peak height ratios remain constant with 
dilution. 
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Figure 21. 
200 >..inm 800 
Absorbance (Al is in arbitrary units. 
Figure 21 shows the effect on the electronic spectrum of the Tc-TPP complex 
caused by the addition of pyridine followed by sodium dithionite reduction. 
Peak height ratios do not vary with dilution. 
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Figure 22. 
A 
200 A/nm 800 
Absorbance (A) is in arbitrary units. 
Figure 22 shows the effect on the electronic spectrum of the Tc-TPPcomplex 
caused by sodium dithionite reduction. Peak height ratios do not vary with 
dilution. 
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Vibrational spectra of porphyrins and metalloporphyrins are difficult to 
obtain due to the high extinction coefficients of the compounds resulting 
in difficulties in the preparation of KBr discs, however one was obtained 
even if it only highlighted the fingerprint region. This showed three extra 
absorptions as compared to He TPP at 979, 900 and 842cm-1 respectively, 
the former possibly representing a Tc=O stretching frequency, however, 
definite interpretation is impossible. 
The green complex appeared to be neutral by electrophoresis under similar 
conditions for the Tc-OEP complex. Unfortunately insufficient solid was 
obtained to allow the measurements of the F AB+ mass spectrum and so 
further characterisation was not possible, except to protract that it is 
probably exactly analogous to the [TcO(OEP)OAc] complex as it seems to 
follow the trends similarly and is also the characteristic green colour. 
Biological evaluation has not yet been performed on this complex. 
3.3 Tetraphenylporphyrindisulphonate Studies. 
As in the previous two cases a characteristically green complex is formed 
in the same manner giving further evidence of a novel general route 
achieving Tc-99 insertion into porphyrins. 
Figures 23 and 24 reproduce electronic spectra of the free base porphyrin 
and the complex respectively. As can be seen there are drastic differences 
between the two spectra. Figure 23 is typical of a free base porphyrin 
spectrum with absorptions at 644, 588, 546, 512nm, the Soret band 
appearing at 413nm. However, the Tc-TPPS2 spectrum has major 
differences with an absorption at 597nm followed by a Soret band split 
into two absorptions (as is the case for OEP) occurring at 421 and 394nm. 
Another feature is the emergence of another absorption at 327 nm (N band). 
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The spectrum of the protonated porphyrin, H4- TPPS2 2+ has absorptions 
at 594, 554 and 422nm (Soreil typical of these species. The electronic 
spectra of the redox reactions of the Tc-TPPS2 complex are reproduced 
in figures 25, 26 and 27. 
Figure 25 shows some drastic changes that occur to the electronic spectrum 
on addition of pyridine to the complex including the emergence of a new 
peak at 302nm. 
Also in the Soret region the peak at 39lnm has a greater absorbance than 
the one at 426nm - a reversal of that found in the complex, however, 
this changes back again on addition of sodium dithionite as shown in figures 
26 and 27. However the addition of reducing agent to the pyridine solution 
causes the band at 300nm to drastically increase in absorbance compared 
to the other absorption peaks, whereas figure 27 shows that addition of 
reducing agent to the Tc-TPPS2 complex on its own shows peaks of absorption 
at 555nm and 346nm that were previously absent. 
The vibrational spectrum of the complex shows only two major additional 
vibrations to that of the free base porphyrin. These occur at 1615cm-1 
and 980cm-1 respectively. The absorption at 1615cm-1 is well within the 
range found for metal-acetate stretching as previously stated [34], and the 
other absorption at 980cm-1 occurs in the region of Tc=O stretching 
frequencies although definite assignment is not possible. 
An F AB+ mass spectrum was requested from Northwick Park Hospital, 
but never received. 
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Figure 23. 
200 Alnm 800 
Absorbance (A) is in arbitrary units. 
Figure 23 shows the electronic spectrum of H2- TPPS2. 
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Figure 24. 
A 
200 Alnm 800 
Absorbance (A) is in arbitrary units. 
Figure 24 shows the electronic spectrum of the Tc-TPPS2 complex, 
displaying a definite split in the Soret band. Extinction coefficients are 
unknown, however peak height ratios remain constant with varying 
concentrations. 
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Figure 25. 
A 
200 800 
A/nm 
Absorbance (A) is in arbitrary units. 
Figure 25 shows the effect on the electronic spectrum of the Tc-TPPS2 
complex caused by the addition of pyridine. Peak height ratios remain 
constant with dilution. 
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Figure 26. 
A 
200 Alnm 800 
Absorbance (A) is in arbitrary units. 
Figure 26 shows the effect on the electronic spectrum of the Tc-TPPS
2 
complex caused by the addition of pyridine followed by sodium dithionite 
reduction. Peak height ratios remain constant with dilution.· 
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Figure 27. 
A 
200 ).Jnm 800 
Absorbance W is in arbitrary units. 
Figure 27 shows the effect on the electronic spectrum of the Tc-TPPS
2 
complex caused by sodium dithionite reduction. Peak height ratios remain 
constant with dilution. 
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The complex is water soluble illld appears anionic by electrophoresis. 
however this could be due to the highly acidic protons on the sulphonic 
acid groups. 
The biological studies were carried out in the same manner as for the 
Tc-OEP complex although the water solubility made the preparation far 
better for injecting. avoiding the need for any solubiIiser. The biodistribution 
results are shown in table 3. 
Table 3- Biodistribution of Tc-TPPS2 complex in abscessed rats. 
<Expressed as an average of four rats') 
% injected dose 
15min. 62min. 3hrs. 5hrs. 8hrs. 4hrs. 
Blood 0.91 0.37 0.35 0.37 0.28 0.25 
Liver 18.7 21.2 19.3 18.5 16.6 14.5 
Spleen 1.4 2.2 1.85 1.7 1.5 1.3 
Lungs 0.77 0.68 0.69 0.71 0.64 0.61 
Kidneys 12.3 21.7 33.8 31.7 28.4 9.8 
Rt. Leg 
0.89 1.07 1.20 1.54 1.25 0.50 (Abscess) 
L. Leg 0.74 0.61 0.52 0.48 0.32 0.31 
Carcass 64.3 42.4 34.6 28.9 27.2 12.85 
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The values show the majority of the activity to be located in the liver and 
kidneys. however it is clear that the abscessed leg has an appreciably greater 
amount of activity associated with it compared to the normal leg. The 
ratios of activity in the abscessed leg: normal leg 2.3 hours after injection 
are shown in table 4. 
Table 4. 
ratio abscessed: normal 
rat I 3.97 
rat 2 2.76 
mean 3.365 
This is appreciably greater than obtained with the Tc-OEP complex. 
probably due to better solubility characteristics 
Figure 28 shows a series of photographs obtained from a static scan taken 
on two rats injected with the preparation. One rat has an abscess in the 
right leg and the other has an internal abscess and also one in the right 
leg. 
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Figure 28.1; 
A. Static. 30 minutes. normal. internal abscess. 
A. Active marker placed on collimator at level of kidneys. 
B. Kidneys. 
C. Abscess. 
B. Static. 1 hour. zoom. internal abscess. 
A. Kidneys 
B. Abscess. 
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Figu re 28 .2: 
A. Sta lic , norma l, inl erna l and leg abscess. 
A. Head. 
8. Rig ht h ind leg ( abscess). 
B. Stalic, 1 hour, density boost. 
A. Head . 
8. Rig ht hind leg (ab scess) . 
C. Ta il. 
c. Stal ic, 1.4 hou rs , density boost. 
A. Head. 
8. Left hind leg (no rma l). 
C. Righ l hind leg (abscess) . 
D. Ta il. 
D. Si a l ic, 1.8 hou rs, dens ity boost. 
A. Head. 
8. Right hind leg (abscess). 
C. Tail. 
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3.4 Phthalocyanine Studies. 
Phthalocyanine (PC) is insoluble in glacial acetic acid, even on prolonged 
heating, and so in this case the synthesis reverted back to using phenol as 
the solvent and hence the phenoxide rather than the acetate would be 
prepared. Figure 29 shows the electronic spectrum of free base 
phthalocyanine with absorptions at 691, 656, 595, 415 and 240nm. By 
comparison the Tc-Pc complex shows absorptions at 669,605 and 412nm 
in the visible region (figure 30> and also at 258nm in the UV. 
The control reaction (equivalent to the formation of the protonated species 
in the previous reactions) of simply phthalocyanine and phenol yields a 
product with absorptions at 688,671,654 and 242nm as shown in figure 
31. The redox reactions of the Tc-Pc complex were carried out in the 
same manner as for the other complexes, however no real changes occurred 
in any of the spectra. This suggests that perhaps ligand exchange reactions 
are not so straight forward with the phenoxide as compared to the acetate. 
Mass spectrum studies have not been performed on this complex and 
preliminary animal studies suggest that the activity is predominantly 
confined to the liver. 
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Figure 29. 
A 
200 )./nm 800 
Absorbance (A) is in arbitrary units . 
. Figure 29 shows the electronic spectrum of phthalocyanine. 
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Figure 30. 
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Figure 30 shows the electronic spectrum of the Tc-Pc complex. 
Ama/nm I /moI-1dm3cm-1 
669 I.28x103 
605 l.32x103 
412 2.21 X 103 
258 8.25x103 
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Figure 31. 
A 
200 )../nm 800 
Absorbance (A) is in arbitrary units. 
Figure 31 shows the visible spectrum of the product from the control reaction 
between phthalocyanine and phenol. 
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4. Conclusions and Future Work. 
In conclusion it can be said that this project achieved its aim in synthesising 
novel technetium-porphyrin complexes of the general formula 
PorphTdO)OAc, via a novel route starting with the metal oxide as opposed 
to the metal acetate, and also carried out preliminary biological evaluation 
tests on most of the complexes synthesised. 
The most logical forward step from here would be to study the reduced 
species that have lost the technetium oxo core and try to develop a preparation 
suitable for injectable purposes. This would provide a potentially valuable 
alternative since most of the present technetium radiopharmaceutica1s 
contain the Tc=O core .. 
Furthermore, it will also be of importance to study in greater detail the 
true biodistribution of these complexes in vivo. These studies should include 
the assessment of the degree of metabolism of such ligands so that an accurate 
idea of the significance of the observed signal can be concluded. This will 
allow a more detailed characterisation of the usefulness of Tc-Iabelled 
porphyrins in the imaging of specific clinical conditions. 
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PART TWO 
The 
Properties of Opioid 
Agonist and Antagonist 
Binding 
CHAPTER 1: GENERAL INTRODUCTION 
1.1 Historical 
Pain is a subjective experience that is interpreted as symptomatic evidence 
of actual or potential tissue damage. Nociception is the nervous process 
giving rise to the sensation of pain and therefore serves a useful function 
in that it signals the presence of an injurious stimulus. The sensation of 
pain is often dependent on the psychological state of the individual. However 
it is not always possible to cure the underlying cause of discomfort and 
as a result drugs that can alleviate the pain and associated anxiety are 
extremely useful. 
Drugs used to relieve pain are known as "analgesics". This term comes from 
the Greek word meaning "painlessness". The main group of compounds 
that are used clinically to relieve severe pain are termed "opioid analgesics". 
The term opioid is derived from the word opium, describing the unripe 
exudate from the poppy Papaver Somniferum. The effects of opium 
were known to the ancient Babylonians around 4000 BC, being used to 
pacify children and as a sleeping draught. Opium first appeared in a medical 
text in China (l000 AD) as a treatment for diarrhoea. 
o 
.•..•. 
... NMe 
Figure 1.1: Morphine 
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In 1803. the chief alkaloid component was isolated from opium by the 
German pharmacist Serturner who called it "morphia" (after Morpheus. 
the Greek god of dreams>. The name morphine is now used in accordance 
with alkaloid nomenclature (figure 1.1>' Although it is the most exploited 
analgesic compound, it also has a range of other pharmacological actions 
(table 1.D. 
Table 1.1: Pharmacological actions of morphine 
Central nervous system 
Analgesia 
Euphoria! dysphoria 
Sedation (although excitation in some species such as cat) 
Antitussive 
Respiratory depression 
Hypotension 
Miosis (pin-point pupils) 
Nausea and vomiting 
Tolerance and dependence 
Peripheral effects 
Constipation 
Bronchial constriction 
Dilatation of cutaneous blood vessels 
Pruritis 
Due to these various effects. but mainly those of euphoria and dependence 
which give rise to abuse potential. a wide range of analogues have been 
synthesised in an attempt to produce an analgesic devoid of unwanted 
properties. However. although many novel and active compounds have 
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been prepared and evaluated morphine is sti11largely the drug of choice 
for severe pain. 
1.2 The Opioid Receptor 
It is necessary to understand the interaction of the drug in a physiological 
system in order to avoid wasted effort in the search for novel compounds. 
Largely the effect of a drug leading to a biological response can be explained 
by an interaction between the drug molecules and a macromolecular complex 
known as a receptor. Various possibilities of interaction exist, for example 
the drug may activate the receptor and thus trigger a response. A compound 
with such effect is known as an agonist. Conversely an antagonist will 
block the effect of an agonist i.e. it has "affinity" for the receptor but no 
"efficacy" to stimulate a response. Some compounds fall between these 
two categories and are known as partial agonists or mixed agonist-
antagonists. Such compounds have affinity for the receptor but can never 
achieve a maximal response compared to a pure agonist. 
Early manipulations of the morphine molecule resulted in antagonists such 
as nalorphine (1) shown in figure 1.2. This compound antagonises the effects 
of morphine (3,4) however nalorphine also produces analgesia (5)' This 
observation led Martin (6) to propose that morphine and nalorphine act 
at different receptors. Other ideas of multiple receptors in agreement with 
this were those of Portoghese (7) based on stereochemical requirements of 
methadone-like compounds. This expanded the concept initially described 
by Beckett and Casy (8), which considered a single receptor. The development 
of naloxone (2, figure 1.3) as a pure antagonist led to the definition of 
opioid receptor involvement in an observed response being sensitive to 
naloxone. 
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Using the chronic spinal dog preparation Martin and colleagues (9-12) 
observedtheeffectsofanumberofmorphinerelatedcompounds.Differences 
in behaviour, sensitivity to antagonism by naloxone and the related antagonist 
naltrexone (figure 1.4), and cross tolerance led them to conclude the presence 
of three different receptors in this preparation each identified with a 
prototypic agonist. Morphine effects were said to be mediated byll - receptors, 
ketocyc1azocine (figure 1.5) by K -receptors and n-allylnormetazocine 
(figure 1.6) by cs -receptors. 
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Figure 1.2: Nalorphine Figure 1.3: Naloxone 
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Figure 1.4: Naltrexone Figure 1.5: Ketocyc1azocine 
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Figure 1.6: N-allylnormetazocine fSKFlO,047l 
In vitro bioassays developed by the Kosterlitz group to examine opioid 
drugs such as the guinea-pig ileum myenteric plexus longitudinal muscle 
and the mouse vas deferens endorsed the existence of opioid 11- and K-
receptors. Electrical stimulation of these tissues elicit contractions which 
can be reduced in a dose-dependent manner by opioid agonists. The 
investigators found that ketocyclazocine along with other benzomorphans 
had only one quarter of the agonist potency in the mouse vas deferens 
as in the guinea-pig ileum compared to normorphine (3). 
Complementary to these bioassays was the development of radioligand 
binding studies, which also added further evidence of a heterogeneous 
population of opioid receptors. Binding assays, unlike pharmacological 
bioassays which measure a response are concerned with the investigation 
of the recognition sites for a particular compound. These recognition sites 
are normally located on a receptor and their interaction with an opioid 
ultimately leads to the biological response. Go1dstein (4) demonstrated the 
stereospecificty of binding by comparing 1evorphano1 (figure 1.7) with its 
(+) isomer dextrorphan. However this only represented 2% of the total 
binding of the tritiated ligand to mouse brain homogenates. The later 
availability of opioids labelled with greater specific activity, initially 
[3HJna10xone and [3HJetorphine, has allowed stereospecific binding of >90% 
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and thus more detailed studies 05-19). 
Figure 1.7: Levorphanol 
Binding of opioids to specific receptor sites is complex and influenced by 
a number of factors. Specific binding is reduced by proteolytic enzymes 
and alkylating agents such as N-ethylmaleimide. This suggests that the 
recognition site occurs in a protein environment with sulphydryl groups 
nearby 05>' Further studies suggested the presence of two thiol groups, 
one close to the binding site on the receptor and one more remote that 
appears to control affinity (84, 85). Opioid binding is also affected by 
temperature and pH (16), and monovalent cations in particular sodium 
05,16,20>. In general agonist affinity is reduced in the presence of NaCl 
whereas the affinity of antagonists is unchanged or even increased (20,2 D. 
This led to the separation of so-called "agonist" and "antagonist" 
conformations of the receptor. 
Subcellular fractionation of brain tissueshowedopioid binding sites to mainly 
occur in the synaptosomal fraction 09,22>' This suggests a location on nerve 
terminals implying a role in synaptic function. 
74 
1.3 Endogenous Opioid Peptides 
It became apparent to investigators that if opioid receptors occur within 
the body then endogenous modulators must exist. Martin (6) suggested that 
'morphine-like compounds might mimic an ongoing biochemical process'. 
In 1975 Hughes and Kosterlitz isolated from porcine brain substances 
possessing opioid-like activity which they termed enkephalins (23), These 
were shown to be two pentapeptides namely [Leu5]enkephalin and 
[Met5]enkephalin, the variation occuring at the C-terminus. Figure 1.8 
shows the enkephalins. Subsequently various extended derivatives of these 
peptides have since been discovered 
The peptide a -lipotropin was shown to contain the [Met5]enkephalin 
sequence as amino acid residues 61-65 (24). Digestion of the peptide by 
trypsin caused release of a so-called C-fragment, residues 61-91 (25). This 
residue was found to exist in porcine pituitary (26) and in isolated tissue 
bioassay had opioid activity thirty times that of [Met5]enkephalin (27). The 
parent peptide a -lipotropin had no such activity and the C-fragment was 
renamed a -endorphin (28). 
A third group of endogenous opioid peptides was isolated by Goldstein (29), 
. 
These were shown to be extensions of [Leu5]enkephalin. Initially a thirteen 
amino acid peptide was discovered to be highly potent in opioid bioassay 
systems and was named dynorphin A(J -13). Subsequently other dynorphin 
fragments have been recognised (see Table 1.2). 
As can be seen from Table 1.2, the three groups of endogenous peptides 
derive from different precursors. The products are released by cleavage 
at basic amino acid residues, thus proenkephalin (A) gives rise to the 
enkephalins (30), a -endorphin is derived from proopiomelanocortin (31) 
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and the dynorphins result from prodynorphin (30), 
HO H 
o O'('N 
HN~N/ 0 
H 
Tyr-Gly-Gly-Phe-R 
H_l-°H 
when R= -Ny 
Leucine 
J-0H 
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Figure 1.8: THE ENKEPHALlNS 
R 
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Opioid Peptide 
[Met5] enkephalin 
[LeuS] enkephalin 
B -endorphin 
Dynorphin A (I - 1 7) 
Dynorphin A (I -13) 
Dynorphin A (I -9) 
B -endorphin is: 
Table 1.2: The Major Endogenous Opioid Peptides 
Precursor Reference 
proenkephalin A 30 
proenkephalin A 30 
proopiomelanocortin A 31 
prodynorphin 29,30 
prodynorphin 29 
prodynorphin 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-VaI-Thr-Leu-
Phe-Lys-Asn-Ala-I1e-IIe-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln 
Dynorphin A (I - 17) is: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-IIe-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln 
However, the use and investigation of natural peptides in both in vitro 
and in vivo systems is hampered by the problems of metabolism and 
degradation (32). These difficulties have in some way been overcome in 
two different manners. In the enkephalins, the substitution of Gly2 with 
D-Ala (33) and Leu5 or Met5 by the corresponding D-isomer (34) has resulted 
in increased agonist potency without affecting receptor selectivity. As an 
alternative inclusion of specific enzyme inhibitors to reduce proteolysis 
at the N-terminus, Gly3 - Phe4 bond and C-terminus has also been successful 
(35). 
The actions of the enkephalins in the guinea-pig ileum and mouse vas 
deferens could not be accounted for in terms of opioid ll-, K- and rJ-
receptors as defined by Martin. [Met5]enkephalin was twenty times more 
potent than normorphine in the mouse vas deferens whilst the two 
compounds were equipotent in the guinea-pig ileum (24), In addition to 
this in the mouse vas deferens the enkephalins required ten times more 
naloxone to antagonise their effects than did morphine. However in the 
guinea-pig ileum the same amount of naloxone would antagonise both 
morphine and the enkephalins (36), From these observations Kosterlitz 
proposed two types of receptor for opioid peptides. These were the ll-
receptor at which morphine acts preferentially and which predominates 
in the guinea-pig ileum and the o-(enkephalin preferring) receptor, 
predominating in the mouse vas deferens. However the K-receptor, for 
which the benzomorphans show selectivity, is also found in the guinea-
pig ileum (36, 37). Subsequently the mouse vas deferens has been shown 
to possess )1-, 0 - and K -receptors (38). Today these are the three recognised 
opioid receptors, with the rJ -site of Martin considered non-opioid, since 
naloxone reversibility. an essential feature of opioid activity is not observed 
(81). This classification was confirmed by binding studies in particular with 
the availability of selective ligands as discussed below. 
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1.4 Improved Selectivity of Drugs 
Structural modification of the enkephalin molecule has been employed to 
improve selectivity at both \1- and 1\ -receptors. For example Tyr-D-Ala-
Gly-MePhe-Gly-ol (DAGOL) is a selective \I-agonist (39.40>. The bis-
penicillamine derivative [D-Pen2• D-pen5]enkephalin (41. figure 1.9) is 
highly 1\ -selective. Not only do these compounds show increased selectivity 
but they are also more stable with greater resistance to proteolysis. 
OH 
..... H H· o. H\(.,H .H H0~/y OMe~ Me~.eO 
Me' s-s~~ 
H 0 
Figure1.9: [D-Pen 2,D-Pen5 ]enkephalin 
The early K-agonists which included compounds such as 
ethylketocyclazocine and bremazocine (figure 1.1 Q) displayed degrees of 
cross-reactivity with \1- and 1\ -sites (42-47>. However by using appropriate 
concentrations of selective agonists to suppress binding at \1- and 1\ -sites. 
a more accurate study of the K -site was possible and confirmed the presence 
of this receptor type in rat and guinea-pig brain (44-46). This was not 
ideal and now more selective K-agonists are available. for example 
U-50488H and U-69593 both made by the Upjohn company (48-50>. 
These two compounds are benzeneacetamide derivatives and differ 
structurally from the peptide and opiate alkaloid nucleus (see figures 1.11 
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and 1.12). Suggestions that these compounds may recognise a subtype of 
the K-opioid receptor are discussed in the following section. 
N~OH 
Figure 1.10: Bremazocine 
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Figure 1.11: U-50488H Figure 1.12: U-69593 
Similarly with antagonists most of the early compounds were unselective 
such as naloxone (2). or showed a small degree of selectivity such as MR2266 
(44). However in more recent years a number of highly selective antagonists 
for all three opioid receptors have become available. such as lel 174864 
(55), These are discussed in more detail later. 
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1.5 Receptor Subtypes 
Perhaps the most controversial aspect of recent opioid research has been 
the subject of opioid receptor sub types. Thus various investigators have 
claimed the presence of subtypes for both It- and K-opioid receptors. 
1.5.1 It-Subtypes 
In 1975 Pasternak and coworkers (61) reported high and low affinity binding 
components using [3H] dihydromorphine and [3HJ naloxone in rat brain 
preparations both by competition and saturation assays. Subsequent analysis 
using the stable peptide [3HID-Ala2, D-Leu5]enkephalin and 
[3HJdihydromorphine in competition assays with a variety of unlabelled 
ligands led them to name the high affinity component It 1 which was claimed 
to be a common site for both opiates such as morphine and peptides such 
as m-Ala2, D- Leu5]enkephalin (62). The low affinity component was 
composed of a It 2-(morphine) site anda 6-(enkephalin)site. Further evidence 
for this It,llt 2 subdivision was revealed by the use of two irreversibly acting 
antagonists. These compounds, namely naloxazone (figure 1.13) and 
naloxonazine (figure 1.14) are based on the structure of naltrexone and 
were claimed to irreversibly eliminate the the high affinity (It 1) component 
(63-65). Because these compounds had the same effect on the binding of 
a series of It -,6 -and K -agonists and someantagonists(65 ,66) the investigators 
suggested that the high and low affinity states did not correspond to 
agonisUantagonist conformations controlled by NaCl. 
Naloxazone and naloxonazine have also been used to evaluate the in vivo 
pharmacological significance of It I-sites in both rats and mice. Pasternak 
and coworkers (67) proposed that It I-sites were responsible for supraspinal 
analgesia, since pretreatment with either naloxazone or naloxonazinecaused 
an 1 I-fold shift in the ED50 of. morphine as measured by tail flick and 
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writhing (68). However, Il, blockade did not alter the respiratory depression 
caused by morphine (68,69) or signs associated with dependence (70), 
HO 0 
N~ 
Figure 1.13: Naloxazone Figure 1.14: Naloxonazine 
1.5.2 K-Subtypes 
In recent years much interest has been focussed upon the K -opioid receptor. 
This is due to the fact that agonists acting at this site display much less 
respiratory depression and euphoria. However, they do exhibit other side-
effects such as psychomimetic actions (70 and sedation (17). 
The first reported suggestion that the K-receptor population was not 
homogeneous and may comprise subtypes appeared in 1982 (72), The binding 
of [3HJethyl ketocyc1azocine to guinea-pig spinal cord, a tissue the authors 
believed contained no Il- or cS - receptors as no binding was observed with 
labelled dihydromorphine or [D':'Ala2, D- Leu5]enkephalin, was shown to 
be heterogeneous. The binding was separated into two components by [0-
Ala2, D-Leu5]enkephalin (DADLE). These two components were named 
K, (DADLE sensitive) and K2 (DADLE insensitive). However these results 
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could be accounted for by the unselectivity of the radioligand and also the 
presence of Il- and <3 -sites (65). More recent studies have shown that 
suppression of these sites still left a non-homogeneous population (J 56). 
The introduction of synthetic K-selective agonists such as U-50488H and 
U-69593 (48,50) appeared to complicate matters further. Tbesecompounds 
and also the endogenous dynorphins have been shown (73,74,48) to recognise 
a subpopulation of K -sites recognised by compounds such as EKe as 
traditionally defined by Martin (1 7). Because of this they appear to displace 
the K -component defined by unselective labelled Iigands such as bremazocine 
and diprenorphine in a biphasic manner (75-77). Morris and Herz (78) 
presented an autoradiographic study of [3HJdiprenorphine (an unselective 
antagonist) in rat brain which demonstrated naloxone sensitive binding sites 
that could not be accounted for in terms of Il-, <3- or K- (U-50488H 
sensitive) sites, and may well therefore be subtypes of the K-opioid site. 
Functional studies have also been employed to try and distinguishK -receptor 
subtypes. Studies (80) suggest that in the mouse vas deferens chronic 
administration of K -opioids causes tolerance. A range ofK -agonists exhibited 
different degrees of cross-tolerance, suggesting heterogeneity. For example, 
vasa from mice tolerant to ethylketocyclazocine (EKO showed only partial 
cross-tolerance towards Mr2034. Another functional assay implying K-
heterogeneity concerns neuroendocrine function. Iyengar and colleagues 
(160) showed that the actions of four K -agonists, Mr2034, U-50488H, EKe 
and tifluadom, in raising plasma corticosterone levels and lowering plasma 
TSH levels were reversed by naloxone, but only the effects of tifluadom 
and EKe were reversed by WIN 44,441-3 (a non- selective antagonist). 
However, many of these agonists are not particularly selective (J 07), and 
so it is difficult to conclude whether subtypes of the K-opioid receptor 
do actually exist. 
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One major problem appears to be in the actual definition of the kappa 
receptor itself, and unequivocable conclusions cannot be made until such 
a definition can be agreed and furthermore a convincing physiological assay 
is designed. This situation may well be aided by Portoghese's recentK -selective 
antagonist norbinaltorphimine (57). Molecular biology techniques which 
will distinguish chemical differences between proteins will provide a 
definitive answer. 
1.6 G Proteins and Opioid Receptors 
Presently most binding assays are performed in low ionic strength buffers 
such as Tris.HCl. However this is far from physiological conditions due 
to a lack of many ions and nucleotides, which control the functioning of 
receptor and effector proteins in the membrane. Consequently such binding 
assays show little correlation with in vitro and in vivo pharmacological 
observations (58)' 
The observation that sodium ions decrease agonist binding without affecting 
antagonist binding was one of the first discoveries in opioid binding 
experiments (20, 82). Similarly, the finding that guanine nucleotides (i.e. 
GTP and analogues) regulate the binding of opioidswas the key that associated 
opioid receptors with G-protein (receptor-controlled guanine nucleotide-
binding regulatory protein) function. Early studies (83-85) showed that 
guanine nucleotides decreased opioid agonist binding in both brain 
membranes and also in neuroblastoma x glioma NG 108-15 cells (86). In 
these preparations the effects were shown to be specific for guanine 
nucleotides, since adenine and other nucleotides were ineffective. Childers 
and Snyder (84,8 5) showed that guanine nucleotideseffectively discriminated 
between agonist and antagonist binding when assays were conducted in the 
presence of sodium ions. The same investigators (85) demonstrated that 
guanine nucleotides increase both association and dissociation rates of opioid 
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binding. Dissociation rates are increased more than association rates and 
the net result of GTP (or analogues of GTP) addition is a decrease in steady-
state binding. 
There are many parallels between the actions of sodium ions and those 
of guanine nucleotides including: 
i) Both sodium ions and GTP affect agonist but not antagonist binding, 
although the maximum agonist-antagonist differentiation of GTP 
effects are seen only in the presence of sodium ions (85). 
iD Both affect kinetics of agonist binding by increasing dissociation rates 
(85)' 
iiil Effects as analysed by Scatchard plots (see chapter 3) of the data are 
confusing with reports of both a decrease in agonist affinity and receptor 
number (Bmax) (87, 82). These contradictions may be explained by 
reference to other receptor systems. For example, with muscarinic 
cholinergic receptors, GTP eliminates agonist binding sites because the 
affinity of agonist binding has decreased to a point where it is not 
detectable in binding assays (88). The net result is a decrease in Bmax 
although the mechanism involves a decrease in affinity. 
iv) The effects of both are specific (83-86). 
v) Reactions involving sulphydryl blocking agents such as N-
ethylmaleimide affect both sodium and guanine nucleotide regulation 
of opioid binding (89)' However, reagent effects are opposite, decreasing 
regulation of binding by guanine nucleotides while increasing regulation 
of binding by sodium. 
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vi) Sodium and guanine nucleotide effects are additive, at least for 
11- and 5-sites (85), although uncertainty surrounds K-sites (90). 
These results suggest that sodium and guanine nucleotides may act at separate, 
though related sites, to regulate opioid agonist binding. The net effect of 
the addition of sodium ions and/or guanine nucleotides appears to shift 
the binding site into a low agonist affinity state. The mechanisms involved 
are not entirely understood. however many ideas are emerging with increased 
knowledge of receptor-effector systems. 
Receptor-controlled guanine nucleotide-binding regulatory proteins 
(G proteins) that function as int,ermediaries in transmembrane signalling 
pathways consist of three major protein groups: receptor. G protein and 
effectors (91). The involvement of a G protein in signal transduction was 
first suggested by the requirement of GTP for hormonal activation of 
adenylyl cyclase (92)' Since then many neurotransmitters including opiates 
(93) have been shown to mediate inhibition of adenylyl cyclase by a GTP-
dependent process. These receptors are sensitive to sodium ions and the 
negative heterotropic effects of guanine nucleotides on agonist binding are 
observed with the same membranes showing the GTP dependency of agonist 
inhibition of adenylyl cyclase (94). These findings suggest that receptor-G 
protein complexes are involved in the inhibitory process. The G protein 
involved in this inhibition of adenylyl cyclase has been termed Gi. This 
protein was isolated and identified following a study of the mechanism 
of action of pertussis toxin elaborated by Bordetella pertussis (95, 96). The 
effects of the toxin on the enzyme adenylyl cyclase appeared to result from 
ADP-ribosylation of a 41-kd membrane protein. Purification of the 
substrate for pertussis toxin revealed a guanine nucleotide-binding protein. 
Other G proteins are also known, Gs stimulates adenylyl cyclase and 
therefore has the opposite effect to Gi. Another G protein exists whose 
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exact function is unknown and is termed Go (99). 
Based on studies of B -adrenergic receptors, DeLean and coworkers proposed 
a ternary complex model (98) to explain agonist specific binding properties. 
The model involves the interaction of the agonist (A), the receptor (R) and 
an additional component assigned X. This component X was postulated 
to represent a G protein <nucleotide binding site). The model is reproduced 
in figure 1.15. 
E* (active) 
nucleotide 
E <inactive) 
Figure 1.15 
More recently Gilman has proposed a cyclic scheme explaining interactions 
of receptor, G protein, nucleotide and effector (99). This scheme is reproduced 
in figure 1.16, and is also based on the B -adrenergic receptor. However, 
it has become accepted as a general model of receptor-G protein interaction 
applicable to opioid systems (59, lOO), 
The interaction between Rand G is antagonised by guanine nucleotide, 
either GTP or GDP. The AR complex stimulates dissociation of G.GDP 
which precedes binding of GTP. AR also stimulates nucleotide binding even 
when most of the bound GDP has been induced to dissociate by interaction 
of G.GDP with AR. The accumulation of significant levels of Gcx.GTP via 
AR-stimulated nucleotide exchange leads to the stimulation of steady-state 
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GTPase activityof the G protein. This, in turn activates the effector system. 
Reconstitution of Rand G results in the establishment of guaninenuc1eotide-
sensitive agonist binding to the receptor. 
1.7: Aims 
G.GDPA 
;<.R.G.GDP 
EG'rf CGTP 
A+R GDP 
Gex.GTP.E * A.R.G.GTP 
precc.:\ ~ 1 Gex.GTP 
Product 
Figure 1.16 
Most binding assays are performed in low ionic strength buffers. The purpose 
of the present project was to characterise opioid binding under conditions 
in which Na+ ions and guanine nuc1eotides are present. Since this results 
in loss of agonist affinity (5 8)1t is likely to be necessary to use [3Hlantagonists 
to accurately define opioid sites under these conditions. Thus the profiles 
a series of selective opioid antagonists were to be studied. Suitable examples 
of these ligands would then be used to further knowledge of opioid binding 
sites and also opioid-sensitive isolated tissue bioassay preparations, and 
therefore provide data more meaningful for comparison of in vitro with 
in vivo studies. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1: Animals 
Male animals were used throughout the study. 
Wistar rats (250-300g) were supplied by the Animal Unit, University of 
Nottingham. 
Dunkin-Hartley guinea-pigs (300-400g) were obtained from David Hall, 
Newchurch, Burton-upon-Trent 
Animals were fed on standard laboratory diet <Pilsbury) and kept in cages 
of 3-6 animals under ambient temperature (20°0, in a dark-light cycle of 
12 hours. Guinea-pig diet was supplemented with vitamin e added to the 
drinking water. 
2.2: Chemicals 
2.2a: General 
Ecoscint A scintillation fluid, National Diagnostics, Somerville, New Jersey, 
U.S.A. 
Trizma Base ITris(hydroxymethyDaminomethane), Sigma, Poole, U.K. 
5'-guanylylimidodiphosphate sodium salt (GppNHp) was purchased from 
Sigma, Poole, U.K. and stored dessicated at -20De prior to use. 
Unless otherwise stated all other chemicals used were of analytical grade. 
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2.2b: Drugs and Peptides 
The following were purchased as shown: 
D-Phe, Cys, Tyr, D-Trp, Om, Thr, Pen, Thr-NH2 (croP), Peninsula 
Laboratories, Wigan, U.K. 
Dynorphin 1-13, [D-Pen2,D-Pen5 Jenkephalin and ICI 174864 
(N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH) arginine salt ( where 
Aib = 0< -aminoisobutyric acid), Cambridge Research Biochemicals, 
Cambridge, u.K. 
Naloxone hydrochloride and [D-Ala2,MePhe4,Gly-oI5Jenkephalin , Sigma, 
Poole, U.K. 
The following compounds were kindly donated as follows: 
Cyprodime hydrobromide [(-)-N -(Cyc!opropylmethyJ)-4, 14- dimethoxy-
-morphinan-6-oneJ and RX8008M (l6-methyl-cyprenorphine): C.F.C. 
Smith, Reckitt and Colman, Hull, U.K. 
(+)SKFlO,047 (N-allylnormetazocine): National Institute on Drug Abuse, 
U.S.A. 
U-S0488H base (trans-3,4-dichloro-N-methyl-N-[2-(I -pyrrolidinyJ)-
cyc!ohexylJ-benzeneacetamide} and U-69593 base {(So<,70<,8B)-(+)-N-
-methyl-N-<7 -(I -pyrrolidinyJ)-I-oxaspiro[4,SJdec-8-yDbenzene-
acetamide: The Upjohn Company, Kalamazoo, U.S.A. 
Xorphanol mesylate: H. Parrs, New York, U.S.A. 
90 
------------------------------------
Norbinaltorphimine hydrochloride and naltrindole hydrochloride: Glaxo 
Group Research. Ware. U.K. 
Ethylketocyc1azocine: Sterling~Winthrop. U.S.A. 
Morphine sulphate: McFarlane-Smith. u.K. 
Fentanyl citrate: Janssen Pharmaceuticals, Sweden. 
ICI204448 {(R,s)-N-[2-(N-methyl-3.4-dichlorophenyl-acetamido)-2-
-<3-carboxyphenyD-ethyIJ-pyrrolidine hydrochloride): 
ICI Pharmaceuticals. Alderley Park. V.K. 
All compounds were stored dessicated as the dry powder or as 1 mM or 10mM 
stock solutions in distilled water or. for dynorphin 1-13. ICI204448. M8008 
and xorphanol mesylate in dimethylsulphoxide. at -20°e. Compounds were 
diluted with distilled water as required before use. 
2.2c: Tritiated ligands 
The following radioligands were obtained from Amersham International plc, 
V.K. : 
rN-allyl-2.3-3HJnaloxone (55 Ci/mmoD. [Phenyl-3.4-3HJU-69593 
(60 Ci/mmoD and U5.16-n-3HJdiprenorphine (48-49 Ci/mmoD. as 
ethanol solutions and stored at -20°e. 
ITyrosyl-3.5-3HJ[D-Ala2.D-Leu5]enkephalin (39.5 Ci.mmoD and 
[Tyrosyl-3.5-3HJ[D-Pen2.D-Pen5]enkephalin (27 Ci/mmol) in 0.05M 
acetic acid. were stored at +4°C. 
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2.3: Ligand Binding Assay Methods 
2.3.1: Buffers 
Ligand binding assays were performed in Tris.HO buffer (50mM, pH 7.4) 
in the absence or presence of 100mM NaCI and 50u M GppNHp as indicated. 
2.3.2: Preparation of homogenates 
Rats or guinea-pigs were sacrificed by cervical dislocation and promptly 
decapitated The brain minus cerebellum of rat and guinea-pig and cerebellum 
of guinea-pig were removed. The tissues were either used immediately or 
stored over liquid nitrogen at -150°C to -180°C for up to one month. 
Central nervous system tissue was homogenised in 10x w Iv Tris.HCI buffer 
(50mM, pH 7.4) using a Kinematica Polytron homogeniser on setting 7 
employing two x ten second bursts. After centrifugation <LKB Hitachi 
Ultrospin, 48,000g for 20 minutes), the supematant was discarded and the 
resultant pellets were resuspended in approximately 20x w Iv Tris.HO buffer 
(50mM, pH 7.4) and incubated at 37°C for 30 minutes in order to facilitate 
degradation and dissociation of endogenous opioid peptides. Following this 
the homogenate was recentrifuged at 48,000g for 20 minutes. The pellets 
were then finally resuspended in 80x wlv of Tris.HO buffer (50mM, pH 
7.4) . The resulting homogenates were used immediately. In assays employing 
Na+ ions the above procedure was carried out with the exception that the 
Tris.HO contained 100mM NaO. 
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2.3.3: Binding Assays 
Competition Assays 
To the final homogenate, containing approximately 0.8 mg/ml protein, the 
primary labelled ligand ,unlabelled competing ligand, water or 1011 M naloxone 
(to define non-specific binding) were added in 20 III aliquots to a final assay 
volume of lml. In cases where suppression of binding to 11-, 6- or K-sites 
was required unlabelled ligands were added as appropriate (outlined in 
pertinent chapters). 50llM GppNHp was added as required. 
The assay tubes were incubated at 25°C for 40 minutes. The assay was 
terminated by the addition of 4ml ice-cold Tris.HCl buffer (50mM, pH 7.4) 
containing 1 OOmM NaCl where necessary followed by rapid filtration through 
Whatman GF /B glass filters either using a Millipore 1225 sampling manifold 
or a Brandel M48R cell harvester. The filters were rinsed three times with 
4ml ice-cold Tris.HCl buffer (50mM, pH 7.4), or where appropriate, ice-
cold Tris.HCl buffer containing 100mM NaCl. The filter discs with retained 
membranes and radioactive residue were transferred to vial inserts and after 
the addition of Ecoscint A, were counted on a Philips PW 4700 liquid 
scintillation counter. Counting efficiency was approximately 40%. The 
determination of ICso values and Hill slopes is outlined in chapter three. 
Saturation Assays 
The assay mixture was as above but varying concentrations of primary labelled 
ligand were used over the concentration range of 0.04-l0nM. Naloxone 
(1 Oil 11) was used to define non-specific binding. The suppression of binding 
to certain opioid sites is discussed in appropriate chapters. Data analysis was 
performed by Scatchard transformation and the program LIGAND as 
discussed in chapter three. 
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Protein Determination 
Protein content was estimated according to the method of Lowry (102), using 
the modification of Schacterle and Pollack (03), 
2.4: Isolated Tissue Bioassay 
2.4.1: Buffer 
Isolated tissue bioassays were performed in Krebs buffer comprising (g/n in 
distilled water: 
NaCI 6.92 
KCI 0.35 
KH2P04 0.16 
CaCI2·2H2O 0.375 
NaHC03 2.1' 
MgS04·7H2O 0.29 
D-glucose 2.0 
2.4.2: Tissue 
The system used was the guinea-pig ileum myenteric plexus longitudinal 
muscle preparation (GPMPLM)' Strips of myenteric plexus logitudinal muscle 
were isolated according to the method of Paton and Zar 000. Tissues were 
mounted in 3ml organ baths containing Krebs solution at 37°C aerated with 
95% O2/5% CO2, 
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2.4.3: Bioassay 
Contractions of the longitudinal muscle were elicited by stimulation through 
platinum ring electrodes mounted above and below the tissues. Pulses with 
a width of OAmsec and a frequency of 0.2Hz were delivered at supramaximal 
voltage, determined daily for each tissue. Contractions were measured 
isotonically using Harvard Bioscience transducers under a tension of 0.8g, 
and recorded on a Washington 480 chart recorder. 
After allowing the tissue 60 minutes equilibration, cumulative dose-response 
curves were constructed for the inhibition of twitch induced by opioid agonists. 
After each agonist the bath fluid was changed by overflow until the twitch 
height returned to control values. To determine the antagonist equilibrium 
dissociation constant (Ke) for naloxone, the antagonist was added to the bath 
for 30 minutes, then without washout, dose-response curves to the agonists 
were reassayed. The Ke value was determined by Schild analysis as discussed 
in chapter three. 
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CHAPTER 3: DATA ANALYSIS 
3.1: Binding Assays 
Determination of radioligand binding constants 
The principle of the law of mass action provides the basis for the following 
binding equations. A simple bimolecular interaction is assumed between a 
drug (D) and its binding site (ID yielding the complex DR. 
At conditions of equilibrium; 
equation 1. 
A measure of the affinity of a ligand for its binding site is known as the 
equilibrium dissociation constant. Ko. where; 
Ko = 
[DJ [R] 
= [OR] equation 2. 
Saturation binding studies 
Saturation experiments can be used to determine the Ko for a radiolabelled 
ligand. The total concentration of radioligand [Dtl is increased and [DR] 
is determined at equilibrium as a function of [DJ since the total binding 
site population [Rtl remains constant. 
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Because [Rt] = [R] + [OR], therefore [R] = [Rt-OR] and so; 
K = o 
[Ri - OR] [DJ 
[OR] 
which can be rearranged to 
[OR] = [Rt] [D] 
Ko+ [D] 
when Ko = [DJ then 
[OR] = [Rt] --
2 
equation 3. 
equation 4. 
equation 5. 
such that the Ko is equivalent to the concentration of radioligand occupying 
50% of the total binding sites. Equation 4 is equivalent to the Langmuir 
adsorption isotherm in that it describes a rectangular hyperbola given by 
[DJ = r 
1 - r 
. when [OR] r = [RtJ 
In this case r represents the proportion of the total potential sites occupied 
by the ligand. 
Scatchard analysis 
Scatchard (104) manipulated equation 4 to give a straight line graph: 
[OR] 
[DJ = 
where; [OR] = B <Specifically bound radioligand) 
[DJ = F (Free radioligand) 
equation 6 
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so that, 
F 
B 
[Rt] = Bmax ITotal number of binding sites) 
= equation 7 
whereupon a plot of B/F versus B yields a slope of -I/Ko and an intercept 
on the abscissa of Bmax. 
B (specifically bound radioligand) represents 
total counts bound - non-specific binding 
F (unbound radioligand) represents 
total counts added - counts specifically bound 
The data can be assessed in terms of concentration by dividing the sample 
dpm by that obtained from the specific activty of the radioligand. Scatchard 
analysis gives a rapid estimation of binding parameters although it has a 
number of inherent drawbacks. 
The bound term is present in both axes and as a result any error will be 
manifested in two dimensions, causing an increase in the scattering of points. 
Another problem arises on transformation of the data from the hyperbolic 
saturation curve to the linear Scatchard plot because the points change from 
being evenly spaced to compressed. This occurs particularly at high 
concentrations of free ligand, resulting in the possibility of a false estimation 
of Bmax. False heterogeneity may also be implied when a methodological 
artefact produces a non-linear plot and conversely true heterogeneity may 
not be observed due to scattering of data points or if the radioligand has 
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a similar affinity at each site. Finally non-weighted linear regression of 
the Scatchard plot is statistically invalid and should be avoided due to non-
uniform errors present in both coordinates of the Scatchard plot. As a result 
computer programs have been developed to overcome these problems. 
The main computer aided system currently employed involves non-linear 
curve-fitting algorithms of the saturation binding isotherm. This is known 
as LIGAND (105), and allows highly accurate estimations of Bmax and Ko. 
This method of analysis has many advantages over conventional Scatchard 
plots in that: 
i) It allows simultaneous analysis of several displacement curves obtained 
for different unlabelled ligands, within an experiment. By combining the 
information a more precise and accurate estimate of common parameters 
is obtained 
ii) It provides direct and explicit statistical testing for alternative models 
or hypotheses. 
Hi) Weighting is provided to compensate for the non-uniformity of variance 
of the dependent variable such as the bound ligand concentration. 
iv) It utilises total ligand concentration as the independent variable and 
total binding rather than specific binding may be examined. This 
eliminates errors caused by subtraction of non-specific binding. 
v) It provides a variety of statistical methods for evaluating the "goodness 
of fit" for a given model. 
However, despite the above comments it is the quality of the original data 
which determines the accuracy and precision of any form of analysis, either 
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manual or computer-aided. 
Competition Binding Analysis 
Competitive inhibition assays can be employed to determine the affinity of 
an unlabelled competing ligand for the binding site. In this method several 
different concentrations of unlabelled competing ligand are employed to 
displace the labelled ligand. It is usual to determine the IC50 of the unlabelled 
competing ligand which is the concentration which results in 50% inhibition 
of the binding of the radioligand. 
In such an experiment both [Rt] and [DJ are constant while the concentration 
of the unlabelled competing ligand [I] is variable. such that at equilibrium 
[OR] is a function of [I] viz. 
[OR] == 
equation 8. 
where [I] == concentration of free unlabelled ligand 
Ki == equilibrium dissociation constant for the interaction of the 
unlabelled ligand with the binding site. 
The function Ki is defined as: 
Ki == [R][l] [RI] equation 9. 
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The IC50 can be used to calculate the equilibrium dissociation constant (Ki) 
for the competing ligand via the Cheng and Prusoff equation (108): 
Ki = 
equation 10. 
It is often difficult to determine the free competing ligand concentration and 
as a result it is assumed that the free concentration is equal to the total 
concentration. However this depends on the amount bound being low <usually 
<10%) with respect to the equilibrium dissociation constant. This means that 
if the total binding sites present are equal to or greater than the equilibrium 
dissociation constant then the Ki value obtained from equation 10 will be 
too high (105). 
Hill Plot 
The transformation of Hill (106) allows linearlisation of a competition 
displacement curve. Rearranging equation 4 gives; 
[OR] 
[Rt] = 
[D] 
equation 11. 
where [DRJ![Rt] is the proportion of binding sites occupied by theradioligand 
and can be renamedr. If this term is substituted into equation 8, rearrangement 
gives 
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[D] = r equation 12. 1 - r 
This describes the interaction of one molecule of radioligand with a single 
binding site. therefore in general terms 
[D]"= r (k) 
1 - r equation 13. 
where n represents the number of radioligand molecules interacting with 
a single binding site and k is a constant. 
A plot of log (r/ l-rl versus log [DJ yields a straight line. the slope corresponding 
to the Hill coefficient. The IC50 is the concentration at which log (r / l-r) = O. 
A slope of unity indicates that the competing ligand is displacing the 
radioligand from a single class of binding sites. or from a heterogeneous 
population of sites for which the competing ligand has the same affinity. 
A shallow slope yielding a Hill coefficient less than one suggests the competing 
ligand is binding to multiple binding sites with different affinities. However 
it could also represent interconverting forms of a single class of binding 
site (I07). A steep slope with a Hill coefficient greater than one implies 
cooperativity of ligand binding. 
3.2: Isolated Tissue Bioassay 
Agonist Dose-Response Curves 
An opioid agonist will reduce the electrically induced twitch of the guinea-
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pig ileum myenteric plexus longitudinal muscle tissue in a dose-dependent 
manner. The amount of inhibition is calculated as follows: 
% inhibition (deflection x 100) = 100 -
original deflection equation 14. 
A plot of % inhibition versus log (agonist concentration) yields a dose-response 
curve from which an IC50 value can be obtained. 
Interaction Between An Agonist And A Competitive Antagonist 
A competitive antagonist may be regarded as a drug that interacts reversibly 
with a set of receptors to form a complex, but the antagonist-receptor 
complex does not elicit a response. The antagonist-receptor interaction 
is characterised by a dissociation constant (K), and as with an agonist, the 
equation for the dissociation constant of the antagonist from the complex 
follows from the law of mass action: 
[A] [R] K = 
A [AR] equation 15. 
where [A] and [AR] represent the concentrations of antagonist 
and antagonist-receptor complex respectively. 
When both an agonist and antagonist for a receptor are present, the 
concentration of free receptors is given by: 
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[R] = [Rt] - [OR] - [AR] 
dividing through by [OR]: 
[R] 
[OR] = 
[RtJ _ 1 _ 
[OR] 
[AR] 
[OR] 
however. [RJlEDR] = Ko/[O] and [AR] = [A][R]/KA. Substituting these into 
the above and rearranging gives: 
[Rt] 
--[OR] = 
KoKA + Ko[A] + KA[O] 
KA[O] equation 16. 
The reciprocal of this equation gives the fraction of receptors occupied by 
the agonist in terms of concentrations and dissociation constants of the agonist 
and antagonist. 
In the presence of a competitive antagonist. the agonist dose-response curve 
is shifted to the right. The curves have the same form. the maximal response 
remains the same and the linear portions of the curve are parallel. The 
essential feature of competitive antagonism is that the effect of the antagonist 
can be overcome by increasing the agonist concentration. 
The degree of shift to the right of the agonist dose-response curve is 
proportional to the antagonist concentration. and the affinity of the antagonist 
for the receptors is inversely proportional to the antagonist-receptor 
dissociation constant KA. The value of KA can be determined from the 
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concentrations of agonist producing equal responses in the absence ([0]0) 
and presence ([oJA) of antagonist. Since the responses are equal. the receptor 
occupancy by the agonist is assumed to be the same. Therefore from equations 
11 and 16: 
[DJ o KA[DJA 
= [DJ O + Ko KoKA + Ko[A] + KAm] 
By taking reciprocals and dividing by the denominators then: 
which reduces to : 
= equation 17. 
When the concentration of antagonist ([AJ2) is such that [DJA = 2[DJo then: 
The value of the antagonist dissociation constant is given by the concentration 
of the antagonist with which the ratio of concentrations of agonist producing 
equal responses in its presence ([DJA) and absence ([0]0) equals 2. 
The negative logarithm of the molar concentration of antagonist with which 
the ratio of equi-effective concentrations of agonist in the presence and 
absence of antagonist is two has been designated by Schild (109) as the pA2 
value. thus: 
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This procedure involves no assumption about the relationship of the" response 
to the proportion of receptors occupied, since the responses are equal and 
it is indepedent of the agonist used, provided that only the antagonist competes 
with the agonist for the receptor. 
Schild Plot 
Equation 17 may be rewritten as: 
[A] 
x-I 
where x = dose ratio, representing 
ICso in presence of A 
ICso in absence of A 
and [A] is the antagonist concentration. 
By using various antagonist concentrations it is possible to construct a plot 
of log (x - 1) versus log [A]x. This gives a straight line, the intercept on the 
abscissa corresponding to the pA2• This can be readily converted to the 
dissociation constant as outlined above. 
The value represented as KA in the preceding scheme is generally referred 
to as Ke, the equilibrium dissociation constant. 
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Single Dose Ke Determination 
The most accurate way to estimate the Ke (or pAz) of an antagonist is by 
way of full Schild analysis. as above. However a quicker method. also devised 
by Schild. gives an approximate value. Instead of using a series of antagonist 
concentrations. just a single dose is chosen. The Ke value is calculated according 
to equation 17. Despite the lower accuracy compared to creating a Schild 
plot, it is often favoured due to time and experimental considerations. 
3.3: Statistical Analysis 
Unless otherwise stated in the text all results are represented as the statistical 
mean ± the standard error of the mean {seml. All experiments were designed 
to conform as far as possible to randomised criteria. Animals used were 
chosen randomly from a large population. The Student's t-test (unpaired) 
was used to determine whether slopes from both Hill and Schild plots 
significantly differed from unity. 
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CHAPTER 4: BINDING PROFILES OF SOME NEWER SELECTIVE 
OPIOIDS/OPIATES 
Introduction 
Selective opioid antagonists are necessary for the unambiguous determination 
of the receptor selectivity of opioid agonists. Although antagonists such as 
naloxone (2) have been used extensively as research tools, the proposed 
existence of multiple opioid receptor types (11-, 6- and K-) has meant a 
need for highly selective antagonists. 
Antagonists were developed showing a certain degree of selectivity such as 
MR2266 (44) and Win 44,441-3 (162). However, one of the first truly 
selective opioid antagonists was ICI 174864 <N,N-diallyl-Tyr-Aib- Aib-
Phe-Leu-OID (55), a peptide based on [Leu5]enkephalin which shows 
selectivity for the <5 -opioid receptor. However, in binding assays the inclusion 
of Na+ ions in the buffer is necessary to obtain an affinity of ICI 174864 
at the <5 -site over both 11- and K -sites in line with its Ke of 30nM determined 
in in vitro bioassay systems such as the mouse vas deferens (21). In the 
absence of Na+ ions an affinity of 200nM is obtained although selectivity 
is retained 
In recent years a number of further antagonists claimed to be selective for 
a single type of opioid receptor have emerged. It is necessary therefore to 
characterise the binding profiles of these newer selective antagonists in order 
that they may be employed to further investigate the properties of opioid 
receptors, and particularly to see if they might help solve the problems of 
receptor subtypes. The compounds chosen to study include: 
Norbinaltorphimine (NorBND, a synthetic bidentateantagonist, with reported 
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selectivity for the K-opioid receptor of >50-fold, both in binding and isolated 
tissue bioassays (57, 51, figure 4.0a). 
Naltrindole, a synthetic indolomorphinan antagonist, reportedly> 1 00- fold 
selective for the 6-opioid receptor, as determined by in vitro bioassays 
(56, figure 4.0b). 
M8008 <I6-methylcyprenorphine), an oripavineantagonistshown to possess 
selectivity for the 6-opioid receptor (2A-fold over ll- and 80-fold over 
K-) in in vitro bioassays (97, figure 4.0d. 
Cyprodime. a synthetic methoxymorphinan antagonist, over 30-fold 
selective for the Il-opioid receptor in isolated tissue bioassays and also 
in preliminary binding assays (54, figure 4.0d). 
D-Phe,Cys, Tyr,D-Trp,Om,Thr,Pen,Thr-NH2 (croP), a synthetic peptide 
analogue of somatostatin, with > I OOO-fold selectivity for the Il-opioid 
receptor (52,53), 
Materials and Methods 
Homogenates of central nervous system tissue were prepared and binding 
assays carried out as described in chapter two. Assays were performed in 
Tris.HCI buffer in the absence and presence of l00mM NaCl and SOil M 
GppNHp . K-Sites were studied in guinea-pig cerebellum homogenates, 6-
sites in NG I 08- IS cells and rat brain homogenates and Il-sites in rat brain 
homogenates. 
RadiolabeIled ligands used to label opioid binding sites were 
[3HJdiprenorphine, [3HJnaloxone, [3HJDADLE and [3HJDPDPE. Details of 
suppressing conditions are described in relevant result sections. Non-specific 
binding was defined throughout with lOll M naloxone. 
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Results 
a) II-Receptor studies 
The affinity of NorBNI at 11- sites was studied both in Tris.HCl buffer and 
with the addition of 1 OOmM NaCl and SOli M GppNHp. II-Sites were studied 
under both conditions using [3HJnaloxone which at a low concentration 
and in rat brain which contains a low level of K-receptors (4S) will mainly 
label II-sites (S 8), due to its slight II-selectivity (l07). 
Figure 4.1 shows NorBNI to displace [3Hmaloxone with low affinity from 
11- sites in both the presence and in the absence of NaCl and GppNHp, 
affording ICso values >SOnM (see table 4.1). 
The displacement of [3HJ naloxone from rat brain homogenates bynaltrindole 
(figure 4.2) afforded an ICso in Tris.HCl of 17.2± 4.4nM and 13.1 ± l.SnM 
in the presence of 100mM NaCl and SOli M GppNHp. Hill coefficients were 
not significantly different from unity (table 4.1). 
Cyprodime displaced specifically bound [3HJnaloxone to II-sites in rat brain 
as shown in figure 4.3, affording an ICso in Tris.HCl of 17.3 ± 3.2nM and 
a Hill coefficient of 0.9S±0.04. In the presence of NaCl and GppNHp the 
affinity was unchanged with an ICso of 28.2± 7.3nM and Hill coefficient 
of 0.94±0.02 (table 4.1). Another II-selective ligand, crop displaced 
[3H]naloxone with high affinity (figure 4.4). In Tris.HCl, crop afforded 
an ICso of 3.09±0.20nM which shifted to a lower affinity <ICso of 18. 7± S.5nM> 
in the presence of NaCl and GppNHp . In both cases Hill coefficients were 
close to unity (1.2±0.1 and 1.03±0.02 respectively). The tailing-off in the 
binding of crop to II-sites is similar to that observed in the displacement 
of labelled naloxone by itself (not shown). 
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As shown in figure 4.S MSOOS readily displaces [3Hmaloxone from rat brain 
homogenates affording an IC50 of 6.0S± 1.6nM and Hill coefficient of 
0.93±0.06 in Tris.HO. Howeverin the presence of 100mM NaOand SOIlM 
GppNHp the concentration inhibition curve for MSOOS shifts approximately 
6-fold to higher affinity (lCso 0.91 ±0.2nMl. 
Table 4.1: Displacement of O.2nM [3m naloxone from rat brain 
homogenates by opioid antagonists 
Tris.HO +NaO/GppNHp* 
Hill Hill 
ICso(nMl Coefficient IC5o(nMl Coefficient 
NorBNI 72.9± S.2 0.6S±0.04$ SO.2± l2.S 0.77±0.1 
Naltrindole l7.2± 4.4 0.S2±0.02$ l3.1± 1.S 0.S2±0.04 
Cyprodime l7.3±3.2 0.9S±0.04 2S.2± 7.3 0.90±0.02 
crop 3.09±0.2 1.20±0.1 lS.7±S.S 1.03±0.02 
MSOOS 6.0S± 1.6 0.93±0.06 0.9l±0.2 0.S6±0.06 
Values represent mean±sem from at least three separate 
determinations. 
*Tris.HO SOmM, NaCI 100mM, GppNHp SOlI M. 
$Indicates Hill coefficient sigriificantly less than unity (P < 0.01) as 
determined by Student's t-test 
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Displacement of (-11}naloxone (0.21 ± 0.02nM) from rat brain homogenates in Tris.HCI (50mM. pH 7.4) 
in the absence (closed symbols) and presence (open symbols) of lOOm M NaCI and 50}-IM GppNHp 
by HorSH!. 
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Displacement of [3Hlnaloxone (0.28 ± 0.04nM) from ral brain homogenates in Tris.HCI (SOmM. pH 7.4) 
in the absence (closed symbols) and presence (open symbols) of 100mM NaCI and SOflM GppNHp by 
cyprodime. 
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Displacement of [3Hlnaloxone (0.86 ± 0.1nM) from rat brain homogenales in Tris.HCI (SOmM. pH 7.4) 
in the absence (closed symbols) and presence (open symbols) of 100mM Noel and SDflM GppNHp by 
MSDDS. 
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b) K-Receptor studies 
NorBNI displaced [3Hldiprenorphine (0.2nM> specifically bound in 
homogenates of guinea-pig cerebellum in Tris.HCI buffer with high affinity. 
However, as seen in figure 4.6 the displacement curve has a biphasic profile. 
Approximately 65% of the binding represented high affinity sites for NorBNI 
affording an ICso of 0.SO±O.05nM (n "" 3), and are thus presumed to be K-
sites. This is supported by studies with the K-selective agonist U-69593 
which displaced a similar amount of specifically bound radioligand with 
an ICso of 16.2 ± 4.8nM. In the presence of I OOmM NaCl and 5()!.1 M GppNHp 
the profile for NorBNI remained the same but shifted to the left, and then 
only for the presumed K-component In contrast the displacement curve 
for the agonist U-69593 shifted some ten times to the right (figure 4.6). 
Although the opiate receptor population in guinea-pig cerebellum is largely 
of the K-type HIO>, this tissue does contain approximately 20% of other 
sites as confirmed above. Thus, in order to study the binding of NorBNI 
to a more homogeneous population of K -binding sites the displacement 
experiments were repeated in the presence of the alkaloid M8008 (figure 
4.Oc). This compound is an opiate antagonist, which has a 30-fold selectivity 
for Il- and an 80-fold selectivity for 6- over K-receptors measured in the 
mouse vas deferens (97). This implies an ability to selectively suppress the 
non-K component of the guinea-pig cerebellum. Although M8008 had not 
been studied in binding assays, its selectivity for Il-and 6-over K-sites was 
confirmed (this study). Assuming published affinities at the three receptor 
types for diprenorphine (107) of 1l-0.84nM, 6-1.42nM and K- 2.24nM, 
and M8008 (97) of Il- l.77nM, 6- O.73nM and K- 59.6nM, and employing 
the occupancy equation 8 (chapter three) a 20nM concentration of the latter 
antagonist will have the effect of increasing the K-component of opioid 
binding in the guinea-pig cerebellum to approximately 94% of the total 
opioid sites. Figure 4.7 shows a theoretical plot of the displacement of 
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[3HJdiprenorphine by MSOOS from guinea-pig cerebellum homogenate 
. which demonstrates this, and the actual displacement as represented in figure 
4.11 confirms that MSOOS recognises a non K-component in this tissue. 
The ability of NorBNI to displace [3HJdiprenorphine (O.26±O.04nM) from 
such defined K-sites is shown in figure 4.S. An approximate lO-fold shift 
to higher affinity in the presence of Na+ ions and GppNHp is again observed, 
however shallow Hill slopes were still obtained (table 4.2). 
The 0 -antagonist naltrindole displaced specifically bound [3HJ diprenorphine 
in the presence of 20nM MSOOS from guinea-pig cerebellum homogenates 
with low affinity (figure 4.9). In Tris.HCl an IC50 of 63.5±20.7nM was 
observed compared to 24.0± 5.3nM in the presence of IOOmM NaCl and 
5011M GppNHp. 
The two ll-selective ligands cyprodime and crop also showed low affinity 
for K-sites when displacing [3HJdiprenorphine from guinea-pig cerebellum 
homogenates. Figure 4.10 depicts the binding of cyprodime at K-Sites, giving 
an IC50 of >500nM. Hill slopes were consistent with binding to a single class 
of sites (table 4.2). crop exhibited even lower affinity at such defined K-
sites affording only 25% displacement of [3HJdiprenorphine from guinea-
pig cerebellum homogenates at a level of 1 II M. This occurred both in the 
absence and presence of lOOmM NaCl and 5011M GppNHp. Table 4.2 
summarises the data obtained for crop and cyprodime. 
MSOOS has a low affinity for K -sites in guinea-pig cerebellum labelled with 
[3HJdiprenorphine. In Tris.HCl·MSOOS yields an IC50 of 209.4±9.9nM 
compared with lO5.4±23.4nM in the presence of IOOmM NaCl and 5011M 
GppNHp (figure 4.11). Shallow Hill slopes were obtained, confirming the 
presence of the non-K component in this assay (table 4.2). 
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Table 4.2: Displacement of [3Hldiprenorphine (O.3nM) from guinea- pig 
cerebellum homogenates by opioid antagonists. 
Tris.HO +NaO/GppNHp* 
Hill Hill 
ICso(nM) Coefficient ICso(nM) Coefficient 
MSOOS 209.4±9.9 0.S4±0.03 1 OS.4± 23.4 0.6Q±0.07 
NorBNIx 2.S±0.7 O.71±O.2 O.23±O.OS O.S5±O.OS$ 
Naltrindolex 63.5±20.7 O.7S±0.06 24.0±5.3 O.77±O.OS 
Cyprodime S21±22.S 0.62±0.OS S20.6±292 0.9S±0.2 
CTOP >1000 >1000 
Values represent mean ±sem from at least three separate 
determinations. 
*Tris.HO SOmM. NaCl 100mM. GppNHp SO\lM. 
$ Indicates Hill coefficient significantly less than unity (P<O.O 1) as 
determined by Student's t-test. 
x In the presence of 20nM M800S. 
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Displacement of [3H]diprenorphine (0.26 ± 0.03nM) in the presencd of 20nM M8008 from guinea-pig 
cerebellum homogenates in Tris.HCI (50mM. pH 7.4) in the absence (closed symbols) and presence 
(open symbols) of 100mM NaCI and 50,1M GppNHp by NorBNI. 
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Displacement of r3Hldiprenorphine (0.23 ± O.OlnM) from guinea-pig cerebellum homogenates in Tris.HCI 
(50mM. pH 7.4) in the absence (closed symbols) and presence (·'pen symbols) of lOOmM NaCI 
and 50pM GppNHp by cyprodime. 
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Displacement of eH]diprenorphine (0.4 ± O.OBnM) from guinea-pig cerebellum homogenates in Tris.Het 
(SOmM, pH 7.4) in the absence (closed symbols) and presence (01'<3" symbols) of 100mM Noel 
and 50JM GppNHp by MBOOB. 
c) o-Receptor studies 
In Tris.HCl 0 -sites in rat brain were labelled with either [3HJDPDPE or 
[3HlDADLE in the presence of 50nM DAGOL to suppress binding to ll-
sites. In the presence of NaCl and GppNHp these agonist radioligands will 
not bind efficiently due to low agonist affinity under these conditions. Thus 
o -binding under conditions promoting low agonist affinity states was studied 
by employing [3Hldiprenorphine to label 0 -sites in NG 108-15 cell 
homogenates which contain exclusively cS -receptors (11). Such studies were 
performed for NorBNI. However loss of this cell line meant that other means 
had to be found to assess 0- binding under so called "agonist" and "antagonist" 
conditions. Thus it was decided to use rat brain homogenates which contain 
a large number of o-sites (45), Binding sites were labelled with 
[3HJdiprenorphine, employing NorBNI to suppress K-binding and cyprodime 
(crop was not available at the time) to suppress IJ -binding. The results 
in this chapter show cyprodime to have a good IJ/K selectivity (>30-fold)' 
In isolated tissue bioassay (54) cyprodime is claimed to be > lOO-fold selective 
for IJ- over o-receptors. The conditions employed, namely 20nM NorBNI 
and 1.261J M cyprodime create, using the receptor occupancy equation 8 
on a spreadsheet format (52), a homogenate which comprises 88% o-sites, 
although approximately 50% of the original number of cS -sites are occluded. 
The suppressing ligands create a similar final homogenate using any of the 
affinity values determined by different means as shown in table 4.3. 
NorBNI has low affinity for o-sites affording ICso values >60nM both in 
the presence and absence of NaCl and GppNHp (figure 4.12), and no shift 
is observed with the varying buffer conditions. 
Naltrindole displaces labelled [3Hldiprenorphine from rat brain homogenates 
in the presence of 20nM NorBNI and 1.261J M cyprodime with high affinity 
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affording an IC50 of 0.26±0.2nM (figure 4.13), In the presence of 100mM 
NaCl and 501lM GppNHp the affinity of naltrindole increases markedly 
(lCso 1.42 ± 0.6pM>. Under the experimental conditions used the (I -component 
represented approximately 65% of specific [3H]diprenorphine binding. Hill 
coefficients for this (I-component were close to unity ( 0.96±0.2 and 
0.91 ±O.OS respectively). 
Table 4.3: Determination of suppressing conditions to enable (1-
binding assays to be performed in rat brain homogenates. 
1I (I K <Ref) 
% no. sites in rat brain 46 42 12 (45) 
affinity [3H]diprenorphine (nM> 0.84 1.42 2.24 (107) 
Cyprodime affinities (nM>: 
Tris.HCl 17.3 626 521 (chapter4) 
+NaCl/GppNHp 28.2 1020+ 820 (chapter4) 
isolated tissue 55.4 6108 1551 (54) 
NorBNI affinities (nM>: 
Tris.HCl 72.9 62.1 2.5 (chapter4) 
+NaCl/GppNHp 50.2 63.S 0.23 (chapter4) 
isolated tissue 33 20 0.4 (56) 
+This value is an estimate based on the shift at 1I- and K-sites. 
As concentration of [3HJdiprenorphine used is below its Ko then the 
ICso values approximate to the Ki. 
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In Tris.HCl cyprodime displaced [3H]DPDPE from rat brain homogenates 
with low affinity (figure 4.14), giving an ICso of 62S.6 ± 26SnM, confirming 
its usefulness as a suppressing ligand being >30-fold selective for il- over 
1>-sites. The Hill slope was not significantly different from unity (table 4.3>' 
The il- selective peptide crop displaced [3HJDADLE in the presence of 
SOnM DAGOL to suppress binding to il-Sites from rat brain homogenates 
in Tris.HCI with very low affinity. Indeed, only approximately 30% 
displacement was achieved at a concentration of 1 il M. 
The oripavine M8008 displaced [3H]DPDPE (3.S±0.3nM) from rat brain 
homogenates in Tris.HCl with high affinity (figure 4.IS) affording an ICso 
of 4.3±0.S4nM and a Hill coefficient of 0.93±0.07, consistent with binding 
to a single population of sites. Again [3H]diprenorphine in rat brain in the 
presence of 1.26 il M cyprodime and 20nM NorBNI was employed to label 
1>-sites (see earlier). In Tris.HCl M8008 displaced specifically bound 
[3H]diprenorphine to such defined 1> -sites with an ICso of 16.7 ± 1. 9nM. Figure 
4.16 shows that the addition of 100mM NaCl and SOil M GppNHp had no 
effect on the displacement profile acso 21.8± 6.2nM>. In both cases shallow 
Hill slopes were obtained, presumably representing binding to unsuppressed 
il- and K-sites. Table 4.4 summarises the data obtained for ligand binding 
assays at 1> -sites. 
For comparitive purposes naloxone has been determined in this laboratory 
with affinities (Ki/nM) of 0.7±OA at il-sites, 19.8±4.3 at 1>-sites and 
10.1 ± 1.8 at K-sites o SO>' These were determined in Tris.HCI and did not 
change with the addition of 100mM NaCI and SOil M GppNHp. 
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Table 4.4: Displacement from o-sites labelled in rat brain 
homogenates by opioid antagonists 
Tris.HQ +NaQ/GppNHp* 
Hill Hill 
ICso(nM> Coefficient ICso(nM) Coefficient 
NorBNI 62.1±20A· 0.93±0.07 63.8± l.3b 0.97±0.01 
Naltrindole 0.26±O.2c O.96±O.2 O.OOI4±O.OO06c 0.91±O.08 
Cyprodime 625.6±265d O.72±O.l nt 
crop >1000· nt 
M8008 4.31±O.5d 0.93±0.07 21.8±6.2c 0.62±0.06$ 
16.7± 1.9c 0.62±0.01 $ 
Values represent mean±sem from at least three separate 
determinations. 
*Tris.HCI 50mM, NaCI 100mM, GppNHp 5011 M. 
$Indicates Hill coefficient significantly less than unity (P < 0.01) as 
determined by Student's t-test 
Definition of binding sites as follows: 
a: [3HJDADLE (0.90±0.lOnM> in the presence of 5011M DAGOL. 
b: [3HJdiprenorphine (0.30± O.02nM) in NGl 08-15 cell homogenates. 
c: [3HJdiprenorphine (0.65±O.04nM) in the presence of 1.2611M 
cyprodime and 20nM NorBNI. 
d: [3HJDPDPE (3.5±0.3nMl. 
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Displacemenl of ('H]DADLE (0.9 ± O./nM) in lhe presence of SOnM DAGOL from rat brain in Tris.HCt 
(SOmM. pH 7.4) by NorSNI (closed symbols). and [3H]diprenorphine (0.3 ± 0.04nM) from NG10B-1S 
cell homogenoles in the presence of 100mM NoCI and SO,t/M GppNHp (open symbols). 
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Figure 4.13 Displacement of eH]diprenorphine (0.64 ± 0.03nM) in the presence of 1.26"M cyprodime 
and 20nM NorBNI from ral brain homogenates in Tris.HCI (SOmM. pH 7.4) in the absence 
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Displacement of ('H]DPDPE (3.78 ± OAnM) from rat brain homogenGtes in Tris.HCI (SOmM. pH 7.4) 
by cyprodime. 
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Displacement of eHjDPDPE (3.5 ± O.3nM) from rat brain homogel'otes in Tris.Het (50mM. pH 7.4) 
by M8008. 
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Displacement of r3H)diprenorphine (0.99 ± O.OlnM) in the presence of 1.26rM cyprodime and 20nM HorSHI 
from rat brain homogenates in Tris.Hel (SOmM, pH 7,4) in the absence (closed symbols) and presence 
(open symbols) of lODmM Noel and 50}tM GppNHp by M8DD8. 
Discussion 
This study has examined the ability of a series of opioidantagoniststocompete 
at !I-, ~- and K-sites in order to determine whether the reported selectivity 
in isolated tissue assays extends to ligand binding assays and whether the 
reported variation of ICI 174864 with altered conditions, that is the presence 
of NaCl and GppNHp is a common phenomenon. 
The results show the ~ -antagonist naltrindole to be by far the most selective 
compound studied. In binding assays in Tris.HCl naltrindoleis 66-foldmore 
selective for ~- over !I-sites and 250-fold more selective for ~- over K-
sites. In the presence of NaQ and GppNHp these figures increase to 
9330-fold and 17000-fold respectively. 
Two !I-opioid receptor antagonists cyprodime and crop were studied. 
Cyprodime is approximately 3D-fold selective for !I- over K- and ~- sites 
whilst the findings confirm the highly !I-selective nature of crop, more 
so than cyprodime. Indeed at both K- and ~-sites I!lM crop could only 
displace approximately 25% of the specific binding of radioligands. 
On the other hand the oripavine antagonist M8008 proved to be the least 
selective of the antagonist compounds tested being almost equieffective at 
!I- and ~-sites. This is shown up in the shallow profiles obtained in the 
displacement of [3Hldiprenorphine from rat brain in the presence of \l-
and K- suppression. Any under-suppression of the !I-component in this 
experiment would result in a flattening of the displacement curve, due 
to lack of selectivity. 
The opioid antagonist NorBNI is confirmed to be K-selective, with 
selectivity ratios (>200-fold) similar to those previously reported (51). 
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These antagonists, in particular naltrindole, NorBNI and croP, being so 
selective should be useful in defining opioid sites. The guinea-pig cerebellum 
is known to contain approximately 80% K -sites, but the remainder is thought 
to be a mixture of Jj - and 6-sites (I 10). Using the above antagonists there 
is evidence for the non-K . component of the guinea-pig cerebellum being 
a population of Jj -sites. This is shown by the displacement of 
[3HJdiprenorphine from guinea-pig cerebellum by cyprodime. A high 
affinity site (presumably Jj -) is observed followed by a much larger and 
lower affinity site representing the K-component. The shallow profile of 
NorBNI at K-sites is evident even in the presence of 20nM M8008 which 
provides a population of 94% K-sites. This may suggest the presence of 
different components to the K-binding profile since antagonists are not 
believed to differentiate different affinity states (58). However the marked 
shift observed for NorBNI at theK-site may relate to it having higher affinity 
for a different state of the receptor. At 6-sites however. naltrindole affords 
Hill slopes of unity even though this compound exhibits marked potency 
shifts under different conditions. 
It is important to realise that binding assays are generally performed in 
low ionic strentgh buffers (for example 117), However. such buffers are 
grossly unphysiological, in particular lacking Na+ and guanine nucleotides 
both of which are known to reduce agonist affinity (58). In the presence 
of NaCI and GppNH p the antagonists naltrindole and NorBNI shift markedly 
to higher affinity at the sites for which they are selective. namely 6- and 
K- respectively but not at the other sites. This property has been reported 
previously for the peptide 6-antagonist ICI 174864 (20. The oripavine 
M8008 shifts to higher affinity at Jj -sites, although not to the same extent 
as naltrindole and NorBNI and apparently does not show this affinity change 
at 6 -sites. In the case of cyprodime no apparent shift in affinity is observed. 
However this is in disagreement with a reported 20-fold shift to higher 
affinity at Jj -sites in the presence of NaCl and GppNHp (54). In agreement 
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with data obtained using [3HJCTOP (52), the affinity at \I-sites decreased 
6-fold in the presence of NaCl and GppNHp. This implies the possibility 
that crop may have some intrinsic activity, since a shift to lower affinity 
in these conditions would be in line with agonist properties (20, 58). 
However according to Paterson (164) crop acts as an antagonist in 
isolated bioassay tissue systems. 
The effects of ions and nucleotides on agonist binding is well documented 
for opioids (20, 58, 82) and a range of other systems such as dopaminergic 
(120), a -adrenergic (121) and a -noradrenergic (122). However, the property 
of antagonists shifting to higher affinity in the presence of NaCl and GppNHp 
appears to be unique to opioids. The closest analogy seems to be the inverse 
agonists of benzodiazepine receptors (123)' These effects shown by particular 
opioid antagonists may be due to molecular properties of the compounds, 
however since they appear to be site-specific the receptor must also be taken 
into account. Costa and Herz have recently reported the inhibition of GTPase 
by the is-antagonist ICI 174864 (153), opposing the effects of agonists which 
stimulate GTPase. They suggest that this action requires a functional G 
protein able to interact with the receptor and that it depends on the receptor 
occupancy by the antagonist. In addition, the degree of activity of the 
antagonist for GTPase is correlated with an ability of the antagonist to 
discriminate between the free and the G protein-bound form of the receptor 
by having high and low affinities. This suggests the compound has some 
form of efficacy, opposing the effects of what are generally considered 
as "true" agonists. Therefore the question arises as to why certain opioid 
compounds behave in such a manner, i.e. respond to NaCl and GppNHp 
by a shift to higher affinity. 
The property has been previously reported (21) with no attempt at 
explanation. At the time it was considered to be associated with the peptide 
structure of ICI 174864, since this antagonist was the first to show such 
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a property. However, an alternative explanation is that this compound was 
the first truly selective antagonist, and all such selective compounds may 
prove to show such a response. In this respect crop would not be expected 
to show a shift as although it is selective it appears to respond in binding 
assays as though it has some agonist properties. 
From a study of the structures it is apparent that all the opioid receptor 
antagonists which show a shift to higher affinity contain unsaturation in 
the same region of the molecule. The double bond in the Cl 7 -C 18 bridge 
of M8008 is in the same spatial area as the indole ring of naltrindole and 
the pyrrole ring of NorBNI as shown in figure 4.17. In the case of ICI 
174864 the phenylalanine <residue 4) can adopt an equivalent position. The 
addition of NaCl and GppNHp could cause a conformational change of the 
protein leading to the unmasking of a hydrophobic area of the receptor 
in the vicinity of where this part of the molecules bind via TT-electrons. 
This would result in the compounds such as naltrindole, NorBNl, M8008 
and leI 174864 being more tightly bound to the receptor for which they 
display selectivity in the presence of NaCl and GppNHp than in its absence 
and consequently exhibiting a higher affinity. The reason why this effect 
occurs only at the site for which the compounds are selective is probably 
one of fit. 
However, if this were simply the reason for the observed shift in affinity 
one may expect compounds such as etorphine (an oripavine like M8008) 
to act in a similar manner. This is not the case, and etorphine acts as an 
agonist under such conditions by shifting to lower affinity (154). Although 
one should note that the compounds displaying a shift in affinity are all 
selective antagonists whereas etorphine is a high intrinsic activity agonist 
with little selectivity. 
In general antagonist properties in opiate molecules are afforded from either 
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an N-allyl or N-cyclopropylmethyl substituent on the piperidine ring of 
the alkaloid nucleus. 
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Figure 4.17 
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This moiety could confer antagonist properties in two ways, either by binding 
to a specific location on the receptor or by forcing the lone pair of electrons 
on the ring nitrogen into such a position that it cannot bind to the receptor 
in a fashion necessary to activate a response. The latter possibility would 
be aided by antagonists containing a l4-0H group, which tend to be the 
purest antagonists such as naloxone. It is likely that the N-aUyl or N-
cyc1opropylmethyl group is the reason for the general lack of effect of NaCl 
and GppNHp on antagonist binding relative to agonist binding. Thus, the 
presence of the C17-C18 double bond in etorphine could be overruled by 
the lack of a suitable N-substituent on the piperidine nitrogen. 
Another observation which can be made is that these antagonists showing 
a shift to higher affinity are all conformationally rigid around C7. The 
addition of NaCl and GppNHp'could conceivably open a 'pocket" in the 
receptor into which the bulky substituents could easily fit and thus apparently 
increase the affinity of the compound. This argument could account for 
NorBNl, naltrindole and possibly also ICI 174864, depending on the 
configuration adopted by the peptide. However the case for M8008 is more 
complex. For M8008, rigidity in this part of the molecule could be achieved 
via intramolecular hydrogen-bonding between the C19-0H and the 
C6-0Me. The occurence of intramolecular C19-0H to C6-0Me hydrogen 
bonding has been demonstrated in the oripavines 024-127), although it is 
only thought to be of importance when large substituents are present on 
Cl9 (124), also the energy difference between the hydrogen-bonded and 
non hydrogen-bonded conformations of M8008 are very low (1 24). However 
diprenorphine, which does not show a shift in affinity (21) has a similar 
structure. This apparent anomaly may be due to the presence in diprenorphine 
of a saturated C17-e18 bridge, and also the lack of selectivity of this ligand 
(1 16), The extra protons would make it impossible for diprenorphine to 
achieve the same hydrogen-bonded structure due to steric overcrowding, 
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as represented in figure 4.18. 
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Figure 4.18 
These factors taken together suggest that the conformational change necessary 
to confer rigidity is only one of a number of equienergetic configurations 
available to the molecule. This could explain the lesser shift in affinity of 
142 
M8008 compared to naltrindole. NorBNI and ICl 174864 
In conclusion. this property of a shift to higher affinity in the presence 
of NaCl and GppNHp may be due to a variety of different parameters, 
probably including molecular interactions between the compound and the 
binding site for which it shows selectivity.These are not meant to be definitive 
reasons for the mechanism behind the shift but plausible explanations. 
However. the fact that these shifts occur cannot be ignored. especially as 
at least one compound in this group appears to have some efficacy in terms 
of GTPase activity (153). 
These observed shifts demonstrate the importance of buffer composition 
in binding assays. If all assays were performed in physiologically relevant 
conditions these shifts would not be known since the compounds would only 
be examined in the context of their physiological environment. The possible 
consequences of such a shift are not immediately apparent since the 
physiologically relevant state is probably the low agonist affinity 
conformation (58)' However. different affinity states may be present even 
though the major state will be of low agonist affinity (5 9). The higher affinity 
values obtained for the antagonists that display a shift are in line with their 
respective Ke values at the pertinent receptor. with the exception of 
naltrindole which shifts to an even higher affinity. These values are 
determined in bioassays under physiological conditions. The reason for the 
difference observed with naltrindole may be due to the presence of Mg++ 
in the bioassay system. but not in the binding assay. This ion is known to 
improve 6-binding (155)' Thus much more information is needed to make 
. conclusions regarding possible conformational changes induced in opiate 
receptor systems in response to agonists and antagonists. 
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CHAPTER 4: Appendix 
The binding profile of the partial agonist xorphanol which is known to 
produce analgesia in man (113, 114) was also determined to complement 
preliminary studies previously carried out in this laboratory. 
Initially the ability of the compound to displace the unselective antagonist 
[3Hldiprenorphine from guinea-pig brain homogenates was determined. 
Figure 4.19 shows that xorphanol displaces the radioligand from opioid 
binding sites affording an IC50 of O.9±O.07nM in Tris.HO and 3.6±0.6nM 
in Tris.HO containing lOOmM NaO and SOIlM GppNHp. In both buffer 
systems xorphanol displayed Hill coefficients close to unity (Table 4.S). 
To determine whether xorphanol had any selectivity binding assays specific 
for 11-, 0- and K-Sites were performed. Figure 4.20 shows the ability of 
xorphanol to displace [3Hlnaloxone from lI-sites in guinea-pig brain. In 
Tris.HO an IC50 of 0.6±O.2nM is achieved whereas in the presence of Na+ 
ions and GppNHp an approximate four fold shift to lower affinity occurs. 
[3HlDADLE in rat brain homogenates was employed to label o-sites in the 
presence of SOnM DAGOL to suppress binding at lI-sites. Figure 4.21 shows 
xorphanol to bind to o-sites with an IC50 of 1.4±O.SnM in Tris.HO and 
a Hill slope of unity. 
Xorphanol displaces [3Hldiprenorphine from guinea-pig cerebellar 
homogenates which can be regarded as an indication of affinity at K-sites 
(figure 4.22). The shift to lower affinity in the presence of 100mM NaO 
and SOli M GppNHp with an IC50 of 1.78 ± 1.3nM compared to 0.4 7 ± 0.1 nM 
in Tris.HO is not so evident at K-sites compared to lI-sites (table 4.S). 
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Table 4.5: Binding Parameters of Xorphanol 
Assay ICso InM 
Hill 
Conditions • Coefficient 
total sites 
TRIS 0.89± 0.Q7 0.94± 0.38 
TRIS-NaCI-
GppNHp 3.6 ± 0.6 0.96± 0.15 
lI-sites 
TRIS 0.62±0.26 0.72±0.16 
TRIS-NaCI-
GppNHp 2.6 ± 0.8 0.84± 0.1 
6-sites 
TRIS 1.4± 0.5 0.99 ±0.08 
K-sites 
TRIS 0.47± 0.1 0.92± 0.04 
TRIS-NaCI-
GppNHp 1.78 ± 1.3 0.79± 0.07 
Values represent mean ± sem from at least three separate determinations, . 
No Hill coefficient was significantly less than unity as determined by 
Student's t-test. 
* TRIS 50mM. NaCl lOOmM, GppNHp 501lM. 
< Definition of binding sites is as follows: 
Total sites: [3Hldiprenorphine (O.22±O.04nM) in guinea-pig brain 
homogenates. 
lI-sites: [3Hlnaloxone (O.28±O.04nM) in guinea-pig brain homogenates. 
6-sites: [3HlDADLE (1.6±0.4nM) in rat brain homogenates in the 
presence of 50nM DAGOL 
K-sites: [3Hldiprenorphine (O.33±O.03nM) in guinea-pig cerebel\um 
homogenates. 
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Displacement of [3H)diprenorphlne (0.22 ± 0.04nM) from guinea-pig brain homogenates in Tris.Hel 
(50mM, pH 7.4) in the absence (closed symbols) and presence (open symbols) of 100mM Nael and 
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Displacement of [3Hlnaloxone (0.28 ± 0.04nM) from guinea-pig brain homogenates in Tris.HCt 
(50mM. pH 7.4) in the absence (closed symbols) and presence (open symbols) of 100mM NaCI and 
50fiM GppNHp by xorphanol. 
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Displacement of ['H)DADLE (1.6 ± O.4nM) in the presence of 50nM DAGOL from rat brain homogenates 
in Tris.HCI (50mM. pH 7.4) by xorphanol. 
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Displacement of ['H]diprenorphine (0.33 ± 0.D3nM) from guinea-pig cerebellum homogenates in Trls.HCI 
(50mM. pH 7.4) in the absence (closed symbols) and presence (opan symbols) of 100mM NaCI and 
50j1lA GppNHp by xorphanol. 
Discussion 
The displacement of [3HJdiprenorphine by xorphanol from guinea-pig 
brain (-cerebellum) homogenates suggests that the compound is unselective 
for different opioid binding sites. This can be concluded from the value 
of unity for the Hill coefficient in a system containing all three recognised 
opioid binding sites in proportions 25% 1.1, 45% 6 and 30% K (49), 
Xorphanol shifts approximately four-fold to lower potency in the presence 
of 100mM NaCI and 501.1 M GppNHp when displacing [3HJdiprenorphine 
from homogenates of guinea-pig cerebellum, a tissue enriched withK -binding 
sites (J 10>. Compounds with high efficacy shift markedly to lower affinity 
under these conditions (for example this study has shown the agonist U69593 
to shift lO-fold to lower affinity). The small shift observed with xorphanol 
suggests that the compound is a weak agonist at K -sites, in agreement with 
isolated tissue data from the guinea-pig myenteric plexus longitudinal muscle 
preparation (I 28)where xorphanol displayed actions charateristicof a partial 
agonist. Furthermore, xorphanol acts as an antagonist in the rabbit vas 
deferens preparation (J 28), a tissue known to contain opioid receptors only 
of the K -type (129), but at which only high efficacy K -Iigands act as agonists. 
A similar small shift to lower potency characteristic of a partial agonist 
is observed in the presence of NaCl and GppNHp when the binding of 
xorphanol to 1.1 -sites labelled with [3HJnaloxone is determined. The 
observation corresponds to data obtained from rat vas deferens bioassays 
where antagonist actions of xorphanol are seen (J 28), although in this tissue 
only high efficacy II-Iigands act as agonists 
In vivo models (J 30) have attributed the pharmacology of xorphanol to 
a predominant K-component, and a smaller, though critical, mu-mediated 
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component This correlates well with the binding data presented herein. 
In binding assays xorphanol was least active at &-sites when displacing 
[3HJDADLE in the presence of 50nM DAGOL from rat brain homogenates. 
However xorphanol may well be an antagonist at &-sites since it antagonises 
DADLE more potently than does ICII74864 in the hamster vas deferens 
(J 3 I), a tissue containing opioid receptors only of the 0 -type (J 32). 
In conclusion it can be said that in terms of binding xorphanol is equipotent 
at both 11- and t<: -sites with lower affinity at & -sites. Phase 11 clinical trials 
(13) reveal xorphanol to be a well-tolerated, orally active analgesic with 
a low dependence-liability and thus is potentially of clinical use. 
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CHAPTER 5: USE OF SELECTIVE ANTAGONISTS TO STUDY THE 
BINDING OF [3H1DIPRENORPHINE TO RAT BRAIN 
HOMOGENA TES 
Introduction 
Data from ligand binding assays has suggested diprenorphine should be 
considered as an unselective antagonist. Although it is generally considered 
as an antagonist diprenorphine does have some agonist properties at the 
K-receptor in the guinea-pig ileum, a tissue with a high receptor reserve 
(12). Reported relative affinities of [3HJdiprenorphine as measured in 
binding assays at 11-, 6 - and K -opioid sites are 0.51,0.3 and 0.19 respectively. 
These figures have led to diprenorphine being referred to as "the almost 
universal antagonist" (16). Indeed [3HJdiprenorphine labels all different 
affinity states of opioid receptors, both "agonist" and "antagonist" forms and 
has been used therefore to investigate binding under conditions 
where Krebs-type buffers rather than the traditional Tris buffers have 
been employed. Under the former conditions opioid agonists do not bind 
well due to a reduced affinity (58, 59). 
One problem with [3HJdiprenorphine however is that it does appear to 
label many more sites than can be explained in terms of conventional opioid 
binding (78, 117>. For example rHJdiprenorphine labels twice the number 
of sites in rat spinal cord than are seen by another unselective ligand 
[3HJbremazocine OS 6>' All of these sites appear to be naloxone sensitive 
confirming their opioid nature. Also Morris and Herz find [3HJdiprenorphine 
binding in brain (78) even when 11 -, 6 - and K - binding is suppressed. 
In spite of the above findings however, in vivo radioligand binding assays 
in the mouse by Frost and colleagues suggest that [3HJdiprenorphine labels 
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mainly the Il-opioid binding site 018>' This conclusion is based on the 
observations that naloxone and all-agonist, carfentanyl, displaced 
[3H]diprenorphine both from the thalamus, which is reportedly enriched 
in Il-sites, and the striatum, which is enriched with &-sites in a manner 
consistent with binding to a single site. However naloxone with a selectivity 
profile of affinities at Il-, & - and K -sites of approimately 2nM, 17 nM and 
27nM (07) is unlikely to distinguish different sites, particularly in vivo 
although carfentanyl displays affinities at 37°C of Il- O.OSlnM, &-4.7nM 
and K-13nM and thus is a selective Il-ligand (1 63). The findings in bioassay 
that diprenorphine shows a 7-fold higher affinity for Il-receptors over 
&- and K-receptors (112) may however lend some support to the results 
of Frost and coworkers. 
~ 
It was decided therefore to reinvestigate the binding of [3HJdiprenorphine 
to rat brain homogenates, a tissue reported to contain Il-, &- and 
K- receptors in the ratio 46, 42% and 12% respectively (45), The aim of 
this work was to tackle some of the inconsistencies which exist in the findings 
with this ligand. In order to establish the binding profile it was intended 
to make use of the antagonists characterised in chapter four. 
Materials and Methods 
Homogenates of rat brain minus cerebellum were prepared and binding 
assays carried out as described in chapter two. Assays were performed 
in Tris.HCl buffer containing IOOmM NaCl and SOil M GppNHp. 
[3HlDiprenorphine was used to label opioid binding sites. Details of 
suppressing conditions are described in relevant results sections. Non-specific 
binding was defined using 10IlM naloxone. 
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Results 
[3HJDiprenorphine bound to homogenates of rat brain in Tris.HCI containing 
100mM NaCI and 50mM GppNHp. At a concentration of 0.5nM the 
specific binding comprised 87.5± 12.5% of the total bound ligand. 
Under the conditions used however there was less than I O%of this specifically 
bound ligand displaced by NorBNI at concentrations «I OnM) consistent with 
its affinity for K-receptors. At increased concentrations NorBNI displayed 
characteristics typical of displacement from a single population of binding 
sites, affording a Hill coefficientofO.94±0.12, and an IC50 of96.05 ± 19.9nM 
(figure 5.1), 
A similar lack of displacement with the 6-antagonist naltrindole was seen 
until a concentration much in excess of that expected to interact with 
6-sites was reached. The obtained results at higher concentrations, 
namely an IC50 of 21.6±4.5nM and a Hill coefficient of 0.82±0.02 is 
again consistent with the idea that this ligand is recognising only a 
single class of sites (figure 5.2), 
The selective d -agonist (+)SKF 10,047 was unable to displace 50% of bound 
[3HJdiprenorphine even at a concentration of 311 M. The displacement curve 
(figure 5.6) suggests that a very small d - component cannot be excluded. 
This contrasts with the work from Herz's laboratory (78) which suggests 
that [3HJdiprenorphine does not label d -sites in rat brain, and the results 
of Tarn (8 J) who finds no activity of diprenorphine at the d -site defined 
with [3HJ(±)EKC. The reasons for the discrepancy are not known but may 
relate to the very low level of d -binding in these tissues. 
The above results appear to confirm that at the level of [3HJdiprenorphine 
used this ligand is binding to a mostly single class of sites which are not 
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K -, 1\ - or a - as defined by displacements with the selective compounds. 
However the ll-antagonists cyprodime and crop (figure 5.3) did not show 
profiles consistent with binding to a single, presumably ll-, site. Both of 
these compounds afforded ICso values approximately ten times greater than 
expected from the data presented in chapter four. This is as a consequence 
of heterogeneous binding as shown up in the shallow Hill coefficients (table 
5.n 
Table 5.1 Displacement of [3Hl diprenorphine (0.3-0.SnMl 
from Rat Brain Homogenates. 
Compound ICso InM Hill Coefficient 
NorBNI 96.1 ± 19.9 0.94± 0.12 
Naltrindole 21.6 ±4.5 0.S2± 0.02 
Cyprodime 21 I ±34 0.70±0.02$ 
crop 363 ± 140 0.64± 0.05$ 
DAGOL 1212±21S 0.4 7 ± 0.04 $' 
Morphine 671±119 0.70± om" 
Fentanyl 457± 31 0.60±0.05~ 
(+)SKF 10,047 ) 3000 -
Values represent mean ± sem from at least three different determinations, 
performed in Tris.HO (50mM, pH 7.4) in the presence of IOOmM NaO 
and 50llM GppNHp. LI I {]p{ os\ $ I..,(,.·o/io ,·t:/I (oe/f;'duk ~.....:fk ... ~ v"u Tl'\ ...... "'....:~ O' ,j 
~ Mc.tA.$_,A b ~t-!t 1-- t-~d". . 
The competition of [3Hldiprenorphine binding by the three ll-agonists 
morphine, DAGOL and fentanyl (figures 5.4 and 5.5) was similarly consistent 
with a heterogeneous binding of the radioIigand. Although at high 
concentrations the Iigands are able to displace the bound [3Hldiprenorphine 
very shallow displacement curves were obtained. 
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The results for the displacements are given in table S.1. Because it is not 
known what sites are involved the data is presented as IC50 values with 
no attempt made to convert these to affinities. 
To determine whether the apparently heterogeneous binding to Il-sites 
was due to a small percentage of labelled <5- and K-sites the 
displacement curve for the agonist fentanyl was repeated in the 
presence of the K-antagonist NorBNI and the <5-antagonist naltrindole 
at fifty times their affinity for the pertinent binding sites (lOnM and 
O.lnM respectively). In a further series of experiments the a -agonist 
(+)SKF 10,047 was added to this ·cocktail" at a concentration of 
300nM. Neither of these conditions altered the displacement profile of 
fentanyl against [3HJdiprenorphine (figures S.S and S.7>. 
This final assay was repeated with many more data points (figure S.8) 
in order to analyse the data using the profram LIGAND (lOS) in terms 
of different models. Of five similar assays which were carried out all 
displacements had Hill coefficients lower than 0.5. Three out of the 
five gave data affording a significantly better fit for a two-site over a 
one-site model. The results of analysis by the non-linear curve fitting 
algorithm are given in table S.2. 
Table 5.2: LIGAND Analysis of Fentanyl displacement assay. 
Compound (app) KilnM Bmax/fmoLmg -I 
site 1 38.5± 9 33.8± 6.4 
site 2 1216±442 1O.3± 3.8 
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Displacement of ['H]diprenorphine (0.86 ± 0.06nM) from rat brain homogenates in Tris.HCI (50mM. pH 7.4) 
containing 100mM Noel and 50pM GppNHp by NorBNI. 
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Displacement of [3Hjdiprenorphine (0.34 ± 0.08nM) from rat brain homogenates in Tris.HCI (SOmM. pH 7.4) 
containing 100mM NaCI and 501lM GppNHp by naltrindole. 
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10.0 30.0 100.0 300.0 1000.0 3000.0 10000.0 
Displacing Ligand / nM 
Displacement of ['H]diprenorphine (0.68 ± 0.06nM) from rat brain homogenates in Tris.HCI (50mM, pH 7.4) 
containing 100mM NaCI and 50pM GppNHp by cyprodime (closed symbols) and crop (open symbols). 
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Displacement of eH]diprenorphine (0.41 ± 0.04nM) from rat brain homogenates in Tris.HCI (50mM. pH 7.4) 
containing 100mM NaCI and 50pM GppNHp by DAGOL (closed symbols) and morphine (open symbols). 
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Displacement of [3H]diprenorphine (O.3nM) from rat brain homogenates in Tris.HCI (SOmM, pH 7.4) 
containing 100mM NaCI and SOJ1M GppNHp by fentanyl in the absence (closed symbols) and presence 
(open symbols) of lOnM Nor8NI and O.lnM naltrindole. 
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Figure 5.6: 
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Displacement of [3H)diprenorphine (0.71 ± D.05nM) from rat brain homogenates in Tris.HCI (5DmM, pH 7.4) 
containing 100mM Noel and 5DpM GppNHp by (+ )SKF1D,D4 7. 
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Displacement of [3H)diprenorphine (O.61nM) from rot brain homogenates in Tris.Hel (SOmM, pH 7.4) 
containing 100mM Noel and 50pM GppNHp by fentanyl in the absence (closed symbols) and presence 
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Displacement of r'H]diprenorphine (0.58 ± 0.03nM) from rat brain homogenates in Tris.HCI (50mM, pH 7.4) 
containing 100mM NaCI and 50{lM GppNHp by fentanyl in the presence of 10nM NorBNI, O.1nM naltrindole and 
300nM (+ )SKF1O,04 7_ 
To test out whether the presence of these two sites was due to a lack of 
suppression of 0- and K-binding of [3HJdiprenorphine by the added ligands, 
analysis of the adequacy of suppression used in the eperiments was evaluated 
using the occupancy equation 8 outlined in chapter three and the data 
given in table 5.3. 
Table 5.3: Data for calculation of theoretical occupancy curves. 
il 0 K <Ref} 
% no. sites in rat brain 46 42 12 (45) 
affinity [3Hkiiprenorphine (nM) 0.84 1.42 2.24 (l07) 
affinity NorBNI (nM) 50.2 63.8 0.23 (chapter 4) 
affinity naltrindole (nM) 13.1 0.0014 24.0 (chapter 4) 
[3HJDiprenorphine at 0.5nM labels a binding site population which 
consists of 36% 0-, 7% K- and 57% il-sites based on the above figures. 
From equation 8 [OR] = [0] [Rtl / {Ko (1 + m / KD + [DD the theoretical 
graphs (figures 5.9 and 5.10) showing sequential displacement of 
[3HJdiprenorphine (0.5nM) by firstly NorBNI followed by naltrindole can 
be generated. At the concentrations of suppressing ligands used the loss 
of site numbers is 12% for il-, 98% for 0- and 95% for K- resulting in 
a final population of 97% il-, 2% 0 - and 1% K -sites. However, this could 
be an underestimate of the 'purity' of the preparation since these calculations 
consider a population of sites which contains 36% 0- and 7% K- opioid 
sites labelled at O.5nM [3HJdiprenorphine. In this study <10% of non 
il-sites appear to be labelled 
165 
.. 
" :;; 
" :s 
'0 
!2 
8 
u 
" ;a 
~ 
a. 
sa 
:c 
"'-
.. 
" :;; 
" :a 
] 
" 8 
u 
" ;a 
eo 
:5 
u 
i3. 
a 
:c 
"'-
32 
30 
2e 
28 
24 
.:z:! 
20 
le 
18 
14 
12 
10 
a 
6 
4 
2 
0 
-11 
Figure 5.9: 
26 
Zol. 
22 
ZO 
1a 
16 
'<j 12 
10 
a 
6 
4 
2 
0 
-12 
-9 -7 
-5 -3 
[NorBNIl (M) 
Theoretical plot representing displacement of [3Hldiprenorphine (0.5 nM) by 
NorBNI in rat brain homogenates from K - (0), 0 - (+), \J - (0 ) sites, and total (Xl. 
- -
-10 
-8 
-6 
[Naltrindolel (M) 
Figure 5.10: Theoretical plot representing displacement of [3Hldiprenorphine (0.5 nM) by 
Naltrindole in the presence of 20nM NorBNI in rat brain homogenates from 
K -(0), 15 -( +), \J -<0 ) sites, and total (X). 
Discussion 
From the displacement curves obtained the results suggest that at the 
concentration used (0.5nMHn thepresenceofNa+ ions andguanine nucleotide 
[3HJdiprenorphine is labelling a group of sites of which approximately 90% 
are not representative of 0 -, K - or ff -sites. The present studies may initially 
therefore be interpreted as confirmation of the data of Frost and colleagues 
(118), that [3HJdiprenorphine is largely labelling a il-site following in vivo 
administration in the mouse. An earlier report also considers 
[3HJdiprenorphine to be il- selective, though in this case il- and K -sites 
were not distinguished (134), 
However since earlier in these present studies [3Hldiprenorphine has been 
used to label both K- and o-sites (chapter four) then obviously the results 
must be treated with a great deal of caution. It may be that in the rats 
used in this study, which contain a low number of K-sites (45), the level 
of [3Hldiprenorphine employed is effectively labelling a largelYil -population 
based on its slightly higher affinity for this site (1 12). However by calculation 
the ratio of sites labelled in rat brain homogenates at a [3HJdiprenorphine 
concentration of 0.5nM would be expected to be 57% il-, 36% 0- and 7% 
K-sites. Therefore the published values for affinity of ligands and number 
of sites in rat brain do not quite approximate to the conditions used in 
the present experiments. This may relate to the presence of Na+ ions and 
a guanine nucleotide analogue. In addition it has been previously reported 
that large variations can exist in receptor number, particularly for the 
o-receptor, between species and or strains of animals (I 57). Consequently 
at higher concentrations of radioligand then it could be expected that all 
three opioid receptor sites are likely to be labelled (1 1 7). This would be 
in agreement with the findings of Jones and coworkers. In their work, 
following [l1CJdiprenorphine distribution in the human brain by PET 
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scanning, then all opioid receptors in brain regions appear to be labelled 
(158). 
If it is accepted that [3HJdiprenorphine in these experiments is labelling 
a largely ll-population then the apparent heterogeneity of binding, 
which exists even when binding to other sites is suppressed, must be 
explained. The obvious explanation that binding to 0-, K- and C1 -sites 
is . still present and interfering with the binding does not seem to be 
valid following analysis of the conditions of occupancy. Curve fitting 
analysis of the data using the program LIGAND (105) suggests the 
presence of two sites, one of high affinity· for ll-ligands and one of 
much lower affinity. These findings are in good agreement with the 
results of Werling and colleagues (59) who found K(app) values for 
DAGOL of 23nM and 1700nM in GTP'YS-treated guinea-pig cortical 
membranes and 7315C cells. (GTPYS is, like GppNHp, a stable 
analogue of GTP). 
The findings can be interpreted to suggest the presence of subtypes of the 
ll-receptor. Previously Pasternak and colleagues (62) have described 
111- and 112-sites. The 11l-site is a high affinity site that appears to be a 
common site for opioids, whilst the 112-site is a lower affinity site specific 
fOfll-ligands. For this to be the case in the present experiments the antagonists 
used to suppress binding to non ll- sites would not have to recognise the 
common 11l-site. This is unlikely but may be possible since it is reported 
that the antagonist naloxonazine alkylates specifically the high affinity 
II ,-site (63-65), as discussed in the introduction. 
A more plausible explanation of the heterogeneous binding may be the 
presence of different affinity states of the ll-opioid site. The ll- receptor 
is a G protein linked receptor and is therefore modulated by guanine 
nucleotides and Na+ ions. In Tris buffers ll-ligands bind with high affinity 
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but in the presence of Na + ions and guanine nucleotides high affinity agonist 
binding is lost (58, 59). Antagonists are generally considered to bind equally 
well to both states of the receptor, although results in chapter four suggest 
that binding of certain of these compounds may be improved under these 
conditions. Therefore it is surprising that the antagonists cyprodime and 
crop show shallow displacement profiles, however from the data in chapter 
four there is a possibility that both compounds may display partial agonist 
properties and therefore be able to distinguish different affinity states. 
Carroll and coworkers (58) have compared binding in the low ionic strength 
buffer HEPES with that seen in Krebs buffers containing GppNHp where 
a low affinity of binding results. Importantly binding under the latter 
conditions correlates very well with affinities of !I-ligands determined in 
isolated tissue bioassay, suggesting that this Iow affinity form may be the 
physiologically relevant receptor. 
The factthat & - and K - antagonist Iigands have been used to suppress binding 
to these sites probably rules out any involvement of low affinity &- or 
K-sites in the observed heterogeneity of !I-binding. 
Following on from these discussions the high levels of [3Hldiprenorphine 
binding previously reported (78, 117) can be explained on the basis of the 
presence of different states of opioid receptors. Thus the hypothesis can 
be proposed that [3Hldiprenorphine labels more sites than other ligands 
such as [3HJbremazocine because it recognises all affinity states of opioid 
receptors whilst other [3HJIigands do not. This may mean a re-estimate 
of receptor site number determined using [3HJagonist ligands is necessary. 
The role of G proteins in controlling opioid receptor function is more fully 
discussed in chapter eight. 
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CHAPTER 6: COMPARISON OF AGONIST AND ANTAGONIST 
BINDING IN GUINEA-PIG BRAIN HOMOGENATES 
Introduction 
In chapter five the problem that [3HJdiprenorphine is labelling a greater 
number of sites than other ligands is raised. The hypothesis that this is 
due to different affinity states is considered. Certainly the presence of 
multiple affinity states of opioid binding sites has been demonstrated in 
rat brain membranes for both <5 - (I 00) and ~ -(52)opioidreceptors. Recently 
Werling and co-workers (59) have shown multiple agonist affinity states 
which can be observed in the presence of Na+, Mg++ and GTP analogues 
or on ADP-ribosylation by pertussis toxin which inactivates G protein. 
These experiments have been performed in both ~ - and <5-opioid receptor 
containing cell lines 7315C and NG 108-15 respectively and also guinea-
pig cortical membranes. The results have been explained as different forms 
of receptor-G protein complexes proposed by the cyclic scheme of Gilman 
(99, see introduction). However such different affinity states should not 
be recognised by antagonists (58), although it has been pointed out in chapter 
four that certain antagonists do appear to be able to distinguish different 
affinity states. Importantly however, such compounds do not lose affinity 
for the low agonist affinity state of the receptor. 
The present study has employed the antagonist [3HJdiprenorphine to label 
opioid binding sites in guinea-pig brain homogenates, in order to determine 
if receptor heterogeneity is a true phenomenon. The guinea-pig was chosen 
due to the large numbers of all three binding sites, comprising 25% ~-, 
45% <5- and 30% K-sites (49). Competition and saturation assays were 
performed in buffers of differing ionic strength using selective opioid agonists 
and antagonists. 
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Materials and Methods 
Homogenates of guinea-pig brain minus cerebellum were prepared and 
binding assays carried out as described in chapter two. Assayswer eperformed 
in Tris.HO buffer (SOmM, pH 7.'4) in the absence and presence of lOOmM 
NaO and SOI1M GppNHp. 
[3HlDiprenorphine and [3HJU-69S93 were used to label opioid binding 
sites. Details of suppression at 11- and o-sites are described in relevant 
results sections. Non-specific binding was defined using 1011 M naloxone. 
Scatchard analysis of saturation assays was performed as described in 
chapter three. 
Results 
Displacement of [3HJdiprenorphine in Tris.HCl by the l1-agonist DAGOL, 
o-agonist DPDPE and K-agonist US0488H confirmed the presence of 11-, 
0- and K -sites (figure 6.1). However, each of the antagonists CTOP, 
naltrindole and NorBNI displaced a greater proportion of specifically bound 
[3HJdiprenorphine than the corresponding agonists (figure 6.1). The sum 
of the displacements by the antagonists accounted for most of the bound 
[3HJdiprenorphine whereas this was not the case for the agonists DAGOL, 
DPDPE and US0488H (figure 6.1>. The most marked difference between 
agonist and antagonist was observed in the displacement of 
[3HJdiprenorphine by l1-ligands where DAGOL displaced only 15-20% 
of the specifically bound radioligand while CTOP reduced binding by 40% 
in the same homogenate preparation. A similar difference was observed 
between the o-agonist DPDPE and antagonist naltrindole (figure 6.0. For 
the K-compounds US0488H and NorBNI the different proportions of 
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[3HJdiprenorphine binding displaced in this tissue did not appear to be so 
marked. 
The assays were repeated in Tris.HCl containing IOOmM NaCl and 5011 M 
GppNHp. Under these conditions, at least for ll- and K-sites the agonists 
and antagonists appear to displace similar amounts of specifically bound 
[3Hldiprenorphine (figure 6.2), This could not be confirmed a ~-sites since 
the ~-agonist DPDPE (lOllM) was able to displace only 16% of the bound 
radioligand under these low agonist affinity. conditions. 
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Figure 6.1: Displacement of ['H]Diprenorphine (1.13 ± 0.1nM) from guinea-pig brain 
homogenates in Tris.HCI (50mM, pH 7.4) by: 
A. OAGOL (open squares) and CTOP (closed squares) 
B. U-50488H (open triangles) and NorBNI (closed triangles) 
C. DPDPE (open stars) and Naltrindole (closed stars) 
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Figure 6.2: Displacement of [3H]Diprenorphine (1.01 ± 0.02nM) from gUinea-pig brain homogenates in 
Tris.HCI (50mM, pH 7.4) containing 100mM NaCI and 50flM GppNHp by: 
A. DAGOL (open squares) and crop (closed squares) 
B. U-50488H (open triangles) and NorBNI (closed triangles) 
From the displacement curves shown in figure 6.1 concentrations of the 
antagonists crop (300nM) and naltrindole (30nM) were used in subsequent 
assays to suppress binding of[3HJdiprenorphineat 11-and & -sites respectively 
in Tris.HQ . Vnder these conditions displacement of the remaining 
specifically bound [3HJdiprenorphine by the K-agonist V-50488H and 
antagonist NorBNI afforded ICso values of 26.4±0.6nM and 2.8±0.6nM 
respectively (figure 6.3). The displacement profiles were consistent with 
binding to a single population of sites, with Hill coefficients not significantly 
differentfrom unity 0.1 0±0.05 and 1.20± 0.15 respectively). However there 
was a proportion of undisplaced radioligand. 
In order to determine if the undisplaced radioligand was due to a er -
component, the er -agonist (+)SKFlQ,047 was assayed. Figure 6.4 shows 
this ligand to displace approximately 10% of the specifically bound 
[3HJdiprenorphine. From this curve (figure 6.4), it can be seen that 300nM 
(+)SKF 10,047 should be sufficient to occlude any labelled er -sites. The 
displacements by K-ligands were therefore reassessed in the presence of 
crop (300nM), naltrindole (30nM) and (+)SKFlQ,047 (300nM). Both 
V-50488H and NorBNI were then able to fully displace the 
[3HJdiprenorphine in a manner corresponding to binding to a homogeneous 
population of binding sites (Hill coefficients 0.96±0.15 and L16±0.17 
respectively). The profiles are depicted in figure 6.5, V-50488H affording 
an ICso of 32.1 ± 12.0nM and NorBNI 2.4±0.6nM. 
K -Opioid binding sites can be labelled as above using suppression of unwanted 
binding, or alternatively by employing the selectiveK -agonist[3HJU-69593. 
In order to compare these two means of characterising the K -site saturation 
analysis was performed both with [3HJU-69593 and [3HJdiprenorphine 
in the presence of 11-, &- and er -suppression. In order to ensure that <10% 
of total added [3H]diprenorphine was bound, the assays involving 
175 
[3H]diprenorphine were carried out in 250x w/v homogenate. Suppression 
of [3H]diprenorphine binding to the non-K' component was achieved by 
the addition of 300nM croP. 30nM naltrindole and 300nM (+)SKFl 0.047 
per 1 nM labelled ligand. However these conditions seemed inadequate at 
lower «0.3nM> concentrations of radioligand. Based on the reported affinities 
of both labelled ligand (107) and unlabelled ligands as determined in chapter 
four. and use of equation 8 determining receptor occupancy outlined in 
chapter three. supplied on a spreadsheet (52). the ratio of suppressing 
ligand: radioligand does not follow a linear progression. The relationship 
breaks down below the Ko of the radioligand (i.e. at approximately 0.3nM>. 
To compensate therefore at lower concentrations of [3HJdiprenorphine 
common suppressing conditions of 100nM croP. 10nM naltrindole and 
100nM (+)SKFlO.047 were employed. Theoretical curves of Jl- and ~­
suppression are shown in figures 6.8 and 6.9 respectively. 
Figure 6.6 shows that the binding of [3H1U-69593 is saturable. Scatchard 
transformation of this data yields a Bmax of 3.9±0.3 pmol/g wet weight 
of brain and a Ko of 1.1 ± 0.1 nM. In comparison figure 6.7 represents the 
saturated binding curve and Scatchard plot for [3H]diprenorphine in the 
presence of croP. naltrindole and (+)SKFlO.047 affording a Bmax of 
3.6±0.2 pmol/g wet weight and a Ko of 0.21 ±0.08nM. The saturation data 
is summarised in table 6.1. 
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Table 6.1: Saturation analysis of [3HJU-69593 and 
[3Hl diprenorphine binding to Guinea-pig 
brain homogentes. 
Compound Bmax (pmol/g"1 r Ko(nMl 
[3HJU-69593 3.9 ± 0.3* 0.94:1:0.01 tl:!: 0.1 
[3H 1 diprenorphine 3.6± 0.2* 0.9 ±0.04 0.2l:!: 0.08 
* The two Bmax values do not significantly differ as compared by a 
t-test (p<o.os). 
r = correlation coefficient of Scatchard plot 
+ Ig of brain = 57~13.1 mg protein 
[3H]diprenorphine binding was suppressed by the addition of 300nM croP, 
30nM naltrindole and 300nM (+)SKFIO,047 per InM labelled ligand to 
a concentration of O.3nM radioligand. At all concentrations below this 
lOOnM croP, IOnM naltrindole and IOOnM (+)SKFIO,047 were used. 
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Discussion 
The proportion of [3HJdiprenorphine binding in guinea-pig brain 
homogenates that can be attributed to a \I-component differs depending 
on whether the agonist DAGOL or antagonist croP is used Since both 
compounds are highly selective ligands for the \I-opioid receptor with 
selectivity profiles greater than lOO-fold (39, 53) it is unlikely that the 
involvment of other opioid sites can account for this difference. 
The fact that DAGOL displaces less [3HJdiprenorphine than croP in 
Tris.HCl buffer suggests that binding sites in the low agonist affinity form 
exist under these conditions and are susceptible to croP but not to DAGOL. 
Although previuos work (chapter four) shows croP to shift in affinity 
this is only 6-fold and unlikely to prevent croP from recognising both 
high and low affinity components (52). Such different affinity states of 
\I-opioid binding sites have been reported previously (58, 59). However 
in the presence of NaCl and GppNHp the differences in amount of 
displacement by agonist and antagonist become much less noticable, 
suggesting that under these conditions the majority of binding sites are in 
the same (or very similar) affinity states, i.e. low agonist affinity states. 
The apparent different affinity states of the \I-opioid binding site 
presumably represent differently coupled forms of the receptor-G protein 
complex, controlled by metal ions and guanine nuc1eotides (59), as 
schematically represented in the introduction. This is further considered 
in chapter eight. 
Similar arguments apply to the highly selective 6-ligands DPDPE (41) and 
naltrindole (56). Multiple affinity states of 6-opioid binding sites have been 
reported both in NG 108-15 cells 040 and rat brain membranes (100), 
Unfortunately using DPDPE it was not possible to confirm that in the 
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presence of NaO and GppNHp the agonist would displace the same number 
of ~-sites due to its inability to bind under such conditions. However the 
fact that the affinity of DPDPE shifts to such a low value implies a change 
in the affinity state of the binding site. The differences in binding of the 
K-preferring compounds U-50488H (40) and NorBNI (SI> appears to be 
much less notable. The presence of high and low affinity 
[3HJ ethylketocyclazocine sites in rat brain and a high affinity site in guinea-
pig brain has been described by Zukin and colleagues (79). However the 
authors assign these as kl and kz subtypes, rather than affinity states of 
the same receptor protein. 
The observation that even in low ionic strength buffer agonists recognise 
a smaller population of binding sites than antagonists raises doubt over 
assays employing agonists as suppressing ligands. The present study has 
examined the displacement of [3HJdiprenorphine by U-50488H (a K-
selective agonist) and NorBNI (a K-selective antagonist) in the presence of 
crop and naltrindole to occlude binding to ll-and a-sites respectively. 
Under these conditions of antagonist suppression, profiles consistent with 
binding to a single site are obtained. However, a small population of 
undisplaced sites remain which are removed on the inclusion of 
(+)SKFIO,047 in the suppressing conditions. This suggests that previous 
reports of K -heterogeneity in this tissue actually represent under suppression 
of other binding sites due to the use of agonists as occluding ligands. 
Many investigators have inferred the possibility of subtypes, particularly 
of the K-opioid receptor <74,79, 142, 143). However, in terms of binding, 
these claims have been based upon differences seen in competition and 
saturation assays between selective K-agonists such as U-69593 (50) and 
PDl 17302 (74) and non-selective agonists such as ethylketocyclazocine, 
bremazocine or etorphine in the absence and presence of selective 11- and 
~-agonists for suppression of the pertinent binding sites (50,74,142,143), 
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In support of this proposal that different affinity states exist and only part 
for example of the \I-population can be occluded by DAGOL, saturation 
analysis comparing [3H]U-69593 and [3HJdiprenorphine in the presence 
of croP, naltrindole and (+)SKFlO,047 has been performed. The Bmax 
obtained for [3H]u-69593 of 3.9±0.3pmollg wet weight compares 
favourably with that reported by Lahti and colleagues of 3.3pmollg (SOl. 
The structurally similar compound [3H]PDI17302 also shows a Bmax of 
3.4pmollg (74). The Bmax obtained for [3H]diprenorphine in the presence 
of croP, naltrindole and (+}SKFlO,047 of 3.6±0.2pmollg does not differ 
from those obtained with selective ligands. This confirms a lack of difference 
between the selective K-agonist and an unselective ligand using antagonists 
for suppression of non-K binding, and contrasts with previous reports of 
apparent K-heterogeneity (50, 74, 1171. 
Therefore it appears that under the conditions employed in the present 
experiments no heterogeneity of the K-site is evident in guinea-pig brain. 
Furthermore it implies the possibility that previous reports of K-subtypes 
may simply comprise the K-site and a mixture of other binding sites in 
low agonist affinity states that are not adequately suppressed. Pasternak 
has recently suugested the existence of four K-receptors (61). This 
conclusion has been based on biphasic binding profiles of dynorphin Band 
ex -neoendorphin in various membrane preparations, such as the guinea-
pig cerebellum and calf striatum. However, neither of these opioid peptides 
are particularly selective K- ligands (07). One possible reason why K-
subtypes are not seen in the present study could be suppression of one or 
more subtype by the antagonists used to occlude \1- and 6-binding sites. 
However the high selectivity of both crop and naltrindole for \1- and 
6 -sites respectively suggests that neither of these compounds have high 
affinity for a possible K-subtype. In support of this naltrindole and the 
peptide IeI 174864 recognise a similar number of such defined 6-sites, 
in displacement assays. 
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In conclusion, these results offer further evidence for the presence of high 
and low agonist affinity states in binmding assay homogenates. It appears 
that in addition the present study has highlighted a need to carefully calculate 
concentrations of suppressing Iigands in saturation analyses, as shown in 
the theoretical plots of 11- and o-suppression.The assumption of a simple 
linear relationship between radioligand and inhibiting unlabelled ligand 
could result in under suppression of binding at lower concentrations of 
labelled ligand. This would manifest in false estimations of both Ko and 
Bmax. 
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CHAPTER 7: AGONIST ACTIVITY OF A SERIES OF K-AGONISTS 
ON THE GUINEA-PIG ILEUM MYENTERIC 
PLEXUS LONGITUDINAL MUSCLE PREPARATION 
Introduction 
The guinea-pig ileum myenteric plexus longitudinal muscle preparation 
is known to contain 11- and K-opioid receptors (36, 37). Opioid agonists 
are able to inhibit the electrically-evoked contraction of this tissue in a 
dose dependent manner. The addition of naloxone reverses this effect. As 
outlined in chapter three, the presence of such a competitive antagonist 
should shift the agonist dose-response curve to the right in a parallel fashion. 
This allows determination of the affinity of the antagonist for the receptor 
as the equilibrium dissociation constant (Ke). 
The Ke value of an antagonist at a particular receptor should be the same 
measured against any agonist acting selectively at that receptor, since it 
is a property of the antagonist not the agonist. Therefore a method to 
determine whether a group of agonists are acting at the same receptor 
is to compare Ke values of an antagonist against each agonist. 
The generally accepted Ke for naloxone at K-opioid receptors in the 
guinea-pig ileum is in the region of 10-15nM (74, 119). However, 
dynorphin 1-13, a peptide selective for K-opioid receptors (29), has been 
reported to afford a naloxone Ke of around 30nM (29). More recently 
a synthetic K -agonist ICI 204448 has been claimed to yield a similar value 
020>. This could imply the presence of K-opioid receptor subtypes in the 
guinea-pig ileum, which have been implicated by binding assays as outlined 
in the introduction and discussed in chapter six. Although the conclusion 
is made that proposed K-opioid receptor subtypes probably represent 
different affinity states this is not fully proven. Thus since this bioassay 
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would represent a physiologically relevant assay for such subtypes it is 
important to analyse the reported results more closely as the absence of 
such assays has greatly hampered the understanding of possible K-subtypes. 
The present study has therefore compared four agonists namely 
ethylketocyclazocine, U-69593, ICI 204448 and dynorphin 1-13 in this 
system and determined naloxone Ke values for each agonist to try to resolve 
the apparent anomaly. 
Materials and Methods 
Isolated tissue preparations were set up for assay and Schild analysis of 
results performed as outlined in chapter two. Inhibition curves were plotted 
by eye and subsequently transformed to Schild plots for calculation of Ke 
values (see chapter three). 
Results 
The agonist potency of a series of K -opioid agonists was determined on 
the guinea-pig ileum longitudinal muscle myenteric-plexus preparation 
(fable 7.n Following this the agonist potencies were redetermined after 
30 minutes preincubation of the antagonist naloxone. 
Figures 7.1-7.4 show the mean Schild plots calculated for the antagonism 
by naloxone of U-69593, ICI 204448, dynorphin 0-13) and 
ethylketocyclazocine <EKO respectively. The Ke values and slopes obtained 
from the plots are given in Table 7.1. There is no significant deviation 
from unity for any of the Schild slopes(t-test,P<0.005),and with the exception 
of dynorphin 0 -13) the Ke values are similar. To check if the naloxone 
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was reaching equilibrium the assay was repeated for ICI 20444& using 
a 10 minute preincubation of the antagonist. The Ke value for naloxone 
versus IC! 204448 obtained after 10 minutes <16.4±2.9nM. n=S) and 30 
minutes 03.3± 1.6nM, n=4) do not significantly differ (t test. P<O.OOS). 
Table 7.1 Schild Analysis of k-agonists. 
Compound ICSO(nM) naloxone slope n KelnM 
Dynorphin 1-13 2.71± 0.7 34.3±2.9 0.990.0.03 4 
U69593 6.47± 1.6 13.7±O.5 1.04±0.02 4 
ICI204448 0.68± 0.1 13.3 ± 1.6 0.99±0.02 4 
EKC 1.39 12.1 0.93 2 
Unless otherwise indicated values represent mean± semfrom determinations 
using tissues from at least three separate animals. &hild analysis was 
performed using lOOnM, 300nM 'and 1 OOOnM concentrations of naloxone, 
incubated for 30 minutes prior to addition of agonist. 
AJo Sc../MIJ slD.f'C ~~fi"".J.s 4.u It.,,, ... "'...:10 C/,,<O.oS) ..., 
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Schild plot representing the antagonism of U-69593 by naloxone in guinea-pig ileum 
myenteric plexus longitudinal muscle. 
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Schild plot representing the antagonism af ICI204448 by naloxone after 30 minutes 
(closed symbols) and 10 minutes (open symbols) in guinea-pig ileum myenteric 
plexus longitudinal muscle. 
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Schild plot representing the antagonism of dynorphin A(I-13) by naloxone in guinea-pig 
ileum myenteric plexus longitudinal muscle. 
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Schild plot representing the antagonism of ethylketocyclazocine (EKC) by naloxone in 
guinea-pig ileum myenteric plexus longitudinal muscle. 
Discussion 
As expected all of the compounds acted as potent agonists in the guinea-
pig ileum, in agreement with previous reports (29, 74)'Fundamental to the 
theory behind the bioassays is the fact that the Ke for an antagonist acting 
at a particular receptor does not vary on varying agonist at that receptor 
(109), since it is a function of the antagonist not the agonist. Bearing this 
in mind the results presented suggest that in the tissues studied dynorphin 
AO-13) is acting ata different receptor than EKC, U-69593andICI204448. 
This could imply the presence of an endogenous peptide receptor, receptor 
subtypes or subsites on the K-receptor. 
However, in guinea-pig ileum, dynorphin 1-13 and 1-17 exhibit extremely 
high potency acting as agonists at the K-receptor (29, 147). The Keobtained 
of 34.3±2.9nM for the antagonism ofdynorphin 1-13 by naloxone compares 
favourably with previous reports by Goldstein and coworkers (29). The 
agonist ICI 20444 8 has been claimed to afford a similar Ke value for naloxone 
antagonism (19), however in this study a Ke of 13.3± 1.6nM was obtained, 
with a Schild slope of 0.99±0.02. This value was unaltered when the assay 
was repeated with a 10 minute naloxone incubation, ruling out the possibility 
of non-equilibration of the antagonist. Both EKC and U-6 9 5 9 3 gave similar 
results, and other K-agonists such as U-50488H and PDl17302 have been 
shown to be antagonised by naloxone affording Ke values in this region 
(74), 
Kenakin 050 has described situations where anomalous Ke values can be 
obtained from apparently sound assays. For example in a study of s-
adrenoceptors on isolated guinea-pig ileum and trachea it was shown that 
non-equilibration of the antagonist can, upon Schild analysis yield a slope 
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of unity, although an incorrect estimate of antagonist potency is obtained. 
This results in misleading indications of receptor heterogeneity. However, 
in the present study this situation does not apply since the same concentrations 
and incubation times of antagonist were used throughout. 
Although the difference in Ke for dynorphin 0-13) is not great it does 
appear to be a consistent finding and perhaps does suggest that 
dynorphin 0-13) is acting differently to the other K-ligands. However 
it is notable that the difference is seen only with dynorphin 0-13), 
resulting in a Ke value for naloxone more in line with that measured 
at 6-receptors. A problem with this ligand is metabolism to 
[Leu5]enkephalin (58). This however is not important in these 
experiments since [Leu5]enkephalin would be expected to interact with 
i1-receptors in this tissue, for which naloxone has an affinity of 
1-2nM 007>' 
There are reports that dynorphins may act differently from other K-
agonists. Thus, studies on the mechanism of spinal analgesia have shown 
dynorphin 1-13 to have a different profile compared to U-50488H, 
suggesting action through different receptors (I 44>. These conclusions were 
made on observation of a major problem with dynorphin I -13, that is 
on intrathecal administration the peptide induces severe motor dysfunction 
characterised by hind-limb paralysis. However this effect cannot be reversed 
by naloxone suggesting a lack of involvement of opiate receptors. 
Furthermore, at doses below those which produce motor dysfunction, 
dynorphin 1-13 is ineffective in behavioural tests of the nociceptive response. 
Indeed, some investigators have indicated that dynorphin is not interacting 
with any of the three major opioid receptor types in this system (I 45). 
In binding assays Smith and colleagues (45) report that [3H]dynorphin 
is only fully displaced from brain membranes by unlabelled dynorphin, 
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but not by other opioid ligands. From this observation it was postulated 
that dynorphin may act at another, as yet undefined site. However, this 
binding could be non-opioid in nature, depending on how the non-specific 
binding was determined. Further discrepancies have arisen around the 
binding of dynorphin. Zukin (79) has claimed dynorphin 1-17 to compete 
for [3HJEKC binding in a different manner to both U -5048 8H and U -69593. 
Thus the affinity of dynorphin 1-1 7 was shown to be the same in rat and 
guinea-pig brain whereas U-50488H and U-69593 had high affinity in 
guinea-pig brain but very low affinity in rat brain. In guinea-pig cerebellum 
a dynorphin resistant site that does not have properties of ll- or IS - sites 
has been reported in the competition for [3H1EKC and [3H1bremazocine 
labelled binding (46). 
Thus, it is tempting to suggest thatthedifferenceobserved betweendynorphin 
and the other agonists suggests possible subtypes of the K -opioid receptor. 
This is a distinct possibility and the guinea-pig ileum may therefore represent 
a bioassay distinguishing these subtypes. However, naloxone is a non-selective 
antagonist and further work must be performed using other antagonists, 
particularly NorBNI which is highly selective for the opioid K-receptor 
(51, 57). 
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CHAPTER 8: GENERAL CONCLUSIONS 
The present study has confirmed early observations about the effects of 
sodium ions and guanine nucleotides on opioid binding (20). A distinct 
difference is noticable between agonists and antagonists, namely the 
attenuation of agonist affinity compared to the lack of effect on, or even 
potentiation of, antagonist affinity. No similarity between the antagonists 
that shift in the opposite direction to agonists in the presence of sodium 
ions and/or guanine nucleotide is reported for other systems including 
dopaminergic (20), B -adrenergic 02l) and ()( -noradrenergic (22), The 
closest similarity occurs at benzodiazepine receptors (I 23), where "inverse" 
agonists oppose the effect of "true" agonists on the GABA receptor complex. 
However, these compounds are still agonists since they elicit a response, 
whereas the action of antagonists is characterised by their inability to cause 
a response (109), The opioids that shift to higher affinity are all reported 
to act as pure antagonists in isolated tissue systems and in vivo (51, 55, 
56, 57, 97, 148). Therefore, a possible explanation of this property of 
certain opioid antagonists maybe the molecular and stereochemical reasons 
outlined in chapter four, and may not relate to the actual conditions 
seen under the true physiological state. However it will be interesting 
to see if such compounds have some form of intrinsic activity. 
The data reported also adds to evidence for the involvement of G proteins 
with opioid receptors. The early ideas based on the B -adrenergic receptor 
(98) appear to be applicable to opioid systems. DeLean and colleagues stated 
that the major effect of adding guanine nucleotides is to destabilise the 
agonist-receptor-G protein complex, from which both agonist and Gprotein 
can dissociate. This reasoning accounted for shallow agonist displacement 
curves, representing different affinty states of the receptor to which 
antagonists were insensitive. 
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Gilman (137) proposed that the interaction between receptor and G protein 
is driven by the agonist, leading to formation of a high affinity 
agonist-receptor-G protein complex. This complex is a prerequisite for 
effector activation which occurs upon binding of the nucleotide. This cycle 
of events is controlled by the nucleotide which antagonises the receptor-G 
protein interaction by causing dissociation of both the agonist and also the 
G protein into its various subunits (see introduction). 
In the case of the B-adrenergicreceptor the effector has been shown to 
be adenylyl cyclase (98, 99, 137). Opioid receptors have been demonstrated 
to be linked to adenylyl cyclase in NG 108-15 and 7315C cell-lines 
041,59). Electrophysiological evidence (149) supports the involvement of 
GTP in coupling between opioid receptors and K+ ion channels in 
guinea-pig cortex. However, the mechanisms by which G protein activation 
is achieved in ion channel-coupled receptors in cortex or adenylyl cyclase-
coupled receptors in cell cultures cannot be distinguished on the basis of 
effects of nucleotides on agonist binding affinity. 
Using the models proposed by DeLean (98) and Gilman (99), many 
investigators have invoked the existence of multiple affinity states of opioid 
receptors, in terms of different receptor-G protien-nucleotide complexes 
(59, lOO, 141). Opioid agonist effects are believed to be mediated via 
receptor-G protein interactions (59). The high agonist affinity state is seen 
with either a coupling of the receptor and G protein (nucleotide dissociated) 
(37), or by allowing an action of a precoupled G protein on the receptor-
ligand complex (38). The low affinity state on this basis would represent 
a situation where the receptor and G protein are uncoupled, implying that 
the G protein is associated to nucleotide. It is known that receptor and 
G protein can interact in the absence of agonist but the presence of an 
agonist greatly facilitates this interaction, and guanine nucleotides antagonise 
this process (37). Spain and Coscia (00) have suggested at (I-sites. on the 
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basis of guanine nucleotide effects on agonist dissociation rate, that GTP 
may act at more than one regulatory site to influence agonist-receptor-G 
protein interactions. ThUs, it is possible that more than one affinity state 
may be related to the formation of the agonist-receptor-G protein-
nucleotide complex. 
The present study supports these notions as detailed in discussion sections, 
and furthermore, suggests that previous claims of the existence of receptor 
subtypes (50, 62, 74, 79, 117, 142, 143) can be explained on the basis of 
such affinity states. This is particularly relevantin the case of the controversy 
surrounding the possible existence of K -subtypes. The observation that 
[3HJdiprenorphine in the presence of croP, naltrindole and (+)SKFI 0,04 7 
affords the same Bmax as [3HJU-69593 in guinea-pig brain, suggests that 
K-opioid subtypes do not exist in these animals, but that different affinity 
states may exist. This implication highlights the difference between the 
use of agonists and antagonists for suppressing unwanted binding. It is 
distinctly possible that previous investigators using agonists to suppress 11-
and &-binding <79, 117, 143) have not accounted for the fact that 11- and 
<I-sites may be present in low agonist affinity conformations. These low 
affinity sites would not be occluded by agonists and show up in subsequent 
assays possibly as subtypes. However such sites would be suppressed by 
antagonists that bind well to low agonist affinity states. Furthermore, this 
may mean that data generated on binding site numbers using agonists such 
as DAGOL only refers to high agonist affinity states and may not represent 
the total receptor number. Problems also arise when correlating a binding 
site to a physiologically relevant receptor. The findings of Carroll (58) 
suggest the physiological Il-receptor is of low agonist affinity. However, 
the receptor is unlikely to be a totally uncoupled form of the G protein 
and most likely correlates to an intermediate state as shown on the scheme 
in figure 8.1. 
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Figure 8.1: Extension of the DeLean model (98), allowing for a range 
of agonist affinity states. Taken from Werling et al. (59). 
A+R t- A·R (1) 7 
Ji + G·GDP J + G'GDP 
A + R·G·GDP t- A·R·G·GDP (2) 7 
Ji -GDP J -GDP 
A + R'G t- A·R·G (3) 7 
J +GTP J +GTP 
A + R·G·GTP t- A·R·G·GTP (4) 7 
J -G·GTP J -G GTP 
A + R' t- A'R I (5) 7 
Ji J 
A+R L A·R (6) 7 
Despite these findings, the possibilty of K-receptor heterogeneity cannot 
be discounted since evidence from functional studies exists. Thus the isolated 
tissue data presented suggests that in the guinea-pig ileum myenteric plexus 
dynorphin 1-13 may be acting at a different receptor to synthetic K-
agonists such as U-69593, EKC and ICI 204448. To determine if this is 
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in fact the case, studies using the selective antagonists, particularly 
norbinaltorphimine (57) are necessary. Work in this laboratory has found 
dynorphin 1-8 (in the presence of enzyme inhibitors) and U-69593 to be 
antagonised by NorBNI affording similar Ke values, although in this instance 
they showed no difference upon antagonism by naloxone. Thus, a definite 
conclusion cannot be made regarding differences between peptide and non-
peptide K - agonists based on the results of this study. 
In summary, the research performed has provided binding profiles of a 
number of selective opioid antagonists and used these compounds to probe 
the nature of opioid binding sites. Continued use of such antagonists should 
enable a better understanding of opioid receptor systems to be achieved, 
and perhaps answer some fundamental questions such as the existence or 
otherwise of opioid receptor sub types. Furthermore visualisation of the 
distribution of opioid receptors will be greatly aided by compounds which 
can recognise all affinity states. 
203 
REFERENCES. 
I. McCawley E.L., Hart E.R. and Marsh D.F., 1. Amer. Chem. Soc., 
63, 314, 1941. 
2. Blumberg H., Day ton H.B., George M. and Rapaport D.N., Fed. Proc., 
20,311, 1961. 
3. Hart E.R., 1. Pharmacol. Exp. Ther., 72, 19, 1941. 
4. Foldes F.F., Lunn J.N., Moore J. and Brown I.M., Amer. 1. Med. 
Sci., 245, 25-30, 1963. 
5. Lasagna L. and Beecher H.K., 1. Pharmacol. Exp. Ther., 112, 
356-363, 1954. 
6. Martin W.R., Pharmacal. Rev., 19,463-521, 1967. 
7. Portoghese P.S., 1. Med. Chem., 8,609-616, 1965. 
8. Beckett AH. and Casy AF., 1. Pharm. Pharmacal., 6, 986-1001, 
1954. 
9. Martin W.R., Eades e.G., Thompson J.A, Huppler R.E. and Gilbert 
P.E., 1. Pharmacol. Exp. Ther., 197, 517-532, 1976. 
10. Martin W.R., Bell J.A, Gilbert P.E., Sloan J.W. and Thompson J.A, 
NIDA Res. Monogr. Sept., 27-30, 1976. 
11. Gilbert P.E. and Martin W.R., Drug Alcohol Depend., 1,373-376, 
1976. 
12. Gilbert P.E. and Martin W.R., 1. Pharmacol. Exp. Ther., 198, 
66-82, 1976. 
13. Hutchinson M., Kosterlitz H.W., Leslie F.M., Waterfield AA. and 
Terenius L., Br. 1. Pharmacol., 55,541-546, 1975. 
14. Goldstein A, Lowney L.I. and Pal B.K., Proc. N atl. Acad. Sci., 
68,1742-1747,1971. 
15. Simon EJ., Hiller J.M. and Edelman I., Prac. Natl. Acad. Sci., 
70,1947-1949,1973. 
16. Pert CB. and Snyder S.H., Proc. Natl. Acad. Sci., 70,2243-2247, 
1973. 
204 
17. Pert c.B., and Snyder S.H., Science, 179,1011-1014,1973. 
18. Wong D.T. and Horng 1.S., Life Sci., 13, 1543-1553, 1973. 
19. Terenius L, Acta Pharmacol. Toxicol., 37,211-221, 1975. 
20. Pert C.B., Pasternak G.W. and Snyder S.H., Science, 182, 
1359-1361, 1973. 
21. Appe1mans N., Carroll 1.A, Ranee MJ., Simon E.1., Traynor 1.R., 
Neuropeptides, 7, 139-143, 1986. 
22. Pert C.B., Snowman AM. and Snyder S.H., Brain Res., 70,184-188, 
1974. 
23. Kosterlitz H.W. and Hughes J., Life Sci., 17,91-96, 1975. 
24. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill LA., Morgan B.A 
and Morris H.R., Nature, 258, 577-579, 1975. 
25. Bradbury AF., Smyth D.G. and SneU c.R.,1n: The Peptide Hormones: 
Molecular and Cellular Aspects, CIBA Found. Symp. No.41, 
pp61-75 (ChurhilI, London 1976). 
26. Bradbury AF., Smyth D.G., and Snell c.R., In: Peptides, Chemistry, 
Structure and Biology, Proc. IV American Peptide Symp. 
<Meinhofer 1., &1.), pp 609-615, (Ann Arbor Science Inc., Ann Arbor, 
1975). 
27. Bradbury AF., Smyth D.G., Snell c.R., Birdsall N.J. and Hulme E.C., 
Nature, 260, 793-795, 1976. 
28. Li C.H. and Chung D., Proc. NatI. Acad. Sci., 73,1145-1148, 
1976. 
29. Go1dstein A., Tachibana S., Lowney L.I., HunkapiIlar M. and 
Hood L., Proc. Natl. Acad. Sci., 76,6666-6671, 1979. 
30. Hughes 1., Br. Med. Bull., 39, 17-24, 1983. 
31. Smyth D.G., Br. Med. Bull., 39,25-30, 1983. 
32. Hughes 1., Neurosci. Res. Prog. Bull., 13, 55-58, 1975. 
33. Pert C.B., Bowie D.L., Fong B.T.W. and Chang J-K., In: Opiates and 
Endogenous Opioid Peptides (Kosterlitz H.W., Bd,) pp79-86, 
(Elsevier/North Holland biomedical Press, 1976). 
205 
34. Kosterlitz H.W., Lord J.A.H., Paterson SJ. and Waterfield A.A., Br. 
1. Pharmacal., 68, 333-342, 1980. 
35. Corbett A.D., Paterson SJ., McKnight A.T., Magnan J. and Kosterlitz 
H.W., Nature, 299,79-81, 1982. 
36. Lord J.A.H, Waterfield A.A., Hughes J. and Kosterlitz HW., In: 
Opiates and Endogenous Opioid Peptides (Kosterlitz HW., Ed.) 
pp 275-280, <Elsevier/North Holland Biomedical Press. 1976). 
37. Lord J.A.H., Waterfield A.A., Hughes J. and Kosterlitz H.W., Nature, 
267, 495-499, 1977. 
38. Wuster M, Rubini P. and Schulz R., Life Sci., 29,1219-1227,1981. 
39. Handa B.K., Lane A.c., Lord J.A.H, Morgan B.A., Rance MJ. and 
Smith C.F.C., Eur. 1. Pharmacal., 70.531-540. 1981. 
40. Kosterlitz HW. and Paterson SJ., Br. 1. Pharmacal., 73, proc. 
suppl. 299P, 1981. 
41. Mosberg H.I., Hurst R., Hruby VJ., Gee K., Yamamura Hr., Galligan 
J.J. and Burks T.F., Prac. Natl. Acad. Sci., 80, 5871-5874, 1983. 
42. Kosterlitz H.W. and Paterson SJ., Prac. R. Sac. Land., B21O, 
113-122,1980. 
43. Kosterlitz H.W., Paterson SJ. and Robson L.E., Br. 1. Pharmacal., 
73,939-949,1981. 
44. Magnan J., Paterson SJ., Tavani A. and Kosterlitz H.W., 
Naunyn-Schmiedeberg's Arch.Pharmacal.,319, 197-205, 1982. 
45. Gillan M.G.C. and Kosterlitz H.W., Br. 1. Pharmacal., 77, 461-469, 
1982. 
46. Chang J-K., Hazum E. and Cuatrecases P., Prac. Natl. Acad. Sci., 
78,4141-4145, 1981. 
47. Hiller J.M. and Simon E.J., J. Pharmacol. Exp. Ther., 214, 516-519, 
1980. 
48. Piercey M.F., Lahti RA, Schroder L.A., Einsphar FJ. and 
Barsuhn c., Life Sci., 31, 1197-1200, 1983. 
206 
49. Gillan M.G.C.. lin W-Q. Kosterlitz H.W. and Paterson S.1 .• 
Br. 1. Pharmacol.. 79 proc. suppl.. 275P. 1983. 
50. Lahti R.A .• Mickelson M.M .• McCall J.M. and Van Voigtlander P.F .• 
Eur. 1. Pharmacal .• 109.281-284. 1985. 
SI. Takemori AE.. Begonia H.Y.. Naeseth IS. and Portoghese P.S .• 
1. Pharmacol. Exp. Ther .• 246. 255-258. 1988. 
52. Hawkins K.N.. Knapp R.J.. Lui G.K.. Gulya K.. Kazmierski W .• 
Wan Y -P .• Pelton IP .• Hruby V.I. and Yamamura H.I .• 1. Pharmacol. 
Exp. Ther .• 248. 73-80. 1989. 
53. Gulya K.. Pelton IT .• Hruby V.J. and Yamamura H.I.. Life Sci .• 
38.2221-2229. 1986. 
54. Schmidhammer H .• Burkard W.P .• Eggstein-Aeppli L.andSmith C.F.C.. 
1. Med. Chem .• 32. 418-421. 1989. 
55. Cotton R.. Giles M.G .• Miller L. Shaw IS. and Timms D .• 
Eur. 1. Pharmacal .• 97.331-332. 1984. 
56. Portoghese P.S .• Sultana M .• Nagase H. and Takemori A.E .• 1. Med. 
Chem .• 31.281-282.1988. 
57. Portoghese P.S .• Lipowski AW. and Takemori AE.. Life Sci.. 4. 
1287-1292. 1987. 
58. Carroll I.A. Shaw IS. and Wickenden AD .• Br. 1. Pharmacal.. 
94. 625-631. 1988. 
59. Werting LL. Puttfarcken p.s. and Cox B.M .• Mal. Pharmacal.. 33. 
423-431. 1988. 
60. Passarelli F. and Costa T .• J. Pharmacal. Exp. Ther .• 248. 299-305. 
1988. 
61. Pastemak G.W. and Snyder S.H.. Nature. 253.563-565. 1975. 
62. Wolozin B.L and Pastemak G.W .• Prac. Natl. Acad. Sci.. 78. 
6181-6185. 1981. 
63. Pastemak G.W. and Hahn E.F .• 1. Med. Chem .• 23. 674-676. 1980. 
64. Hahn E.F .• CarroII-Buatti M. and Pastemak G.W .• J. Neurosci .• 
2. 572-576. 1982. 
207 
65. Pasternak G.W., Proc. NatI. Acad. Sci., 77, 3691-3694, 1980. 
66. Hahn E.F. and Pasternak G.W., Life ScL, 31, 1385-1388, 1982. 
67. Ling G.S.F. and Pasternak G.W., Brain Res., 27 1,152-156,1983. 
68. Ling G.S.F., Spiegel K., Nishimura S. and Pasternak G.W., Eur. 1. 
Pharmacal., 86, 487-488, 1983. 
69. Ling G.S.F., Spiegel K., Lockhart S.H. and Pasternak G.W., 
1. Pharmacol. Exp. Ther., 232, 149-155, 1985. 
70. Ling G.S.F., MacLeod J.M., Lee S., Lockhart S.H. and Pasternak G.W., 
Science, 226,462-464, 1984. 
71. Pfeiffer A, Brand V., Herz A and Emrich M.H., Science, 233, 
774-7776, 1986. 
72. Attali B., Gouarderes C, Mazarguil H., Audigier Y. and eras ]., 
Neuropeptides, 3, 53-64, 1982. 
73. Traynor J.R., Wood M.s., Carroll J.A and Rance MJ., In: Progress 
in Opioid Research (NIDA Monogr. 75), (Holaday J.W., Law P-Y. 
and Herz A, EOO'> pp 73-76, US Department of Health and Human 
Sciences, 1986. 
74. Oarke CR., Birchmore B., Sharif N.A., Hunter J.C., Hill R.G. and 
Hughes J., Br. 1. PharmacoI., 93,618-626, 1988. 
75. Pfeiffer A, Pasi A., Mehraein P. and Herz A, Neuropeptides, 2, 
89-97, 1981. 
76. Morre M., Bachy A., Grant B., Bioigegrain R., Arnone M. and 
RoncucciR., Life ScL, 33(1),179-182,1983. 
77. Su T-P., J. Pharmacol. Exp. Ther., 223,284-290, 1982. 
78. Morris BJ. and Herz A., Brain Res. 384,362-366, 1986. 
79. Zukin R.S., Eghbali M., Olive D., Unterwald E.M. and Tempel A, Proc. 
NatI. Acad. Sci., 85,4061-4065, 1988. 
80. Wuster M., Schultz R. and Herz A., Biochem. PharmacoI., 30, 
1883-1887, 1981. 
81. Tarn S.W., Proc. NatI. Acad. ScL, 80, 6703-6707, 1983. 
208 
82. Simon E.1.. Hiller 1.M .• Groth 1. and Edelman I .• 1. Pharmacol. Exp. 
Ther .• 192.531-537. 1975. 
83. Blume A.I. Life Sci .• 22. 1843-1852. 1978. 
84. Childers S.R. and Snyder S.H .• Life Sci .• 23. 759-762. 1979. 
85. Childer S.R. and Snyder S.H .• 1. Neurochem .• 34. 583-593.1980. 
86. Blume A.J .• Proc. NatJ. Acad. Sci .• 75. 1713-1717. 1978. 
87. Pert c.B. and Snyder S.H.. Mol. Pharmacol .• 10. 868-879. 1974. 
88. Harden T.K.. Meeker R.B. and Martin H.W .• 1. Pharmacol. Exp. 
Ther .• 227. 570-577. 1983. 
89. Childers S.R. 1. Pharmacol. Exp. Ther .• 230. 684-691. 1984. 
90. Mack KJ .• Lee M.F. and Wehenmeyer lA.. Brain Res. Bull.. 14. 
301-306. 1985. 
91. Gilman A.G .• Trends Neurosci .• 9. 460-463. 1986. 
92. Rodbell M .• Birnbaumer L.. Pohl S.L. and Krans H.MJ .• 1. BioI. Chem .• 
246. 1877-1882, 1971. 
93. Blume A.J .• Lichtstein D. and Boone G .• Proc. Natl. Acad. Sci .• 
76, 5626-5630. 1979. 
94. Rodbell M .• Nature. 284.17-22. 1980. 
95. Katada T .• and Ui M .• 1. BioI. Chem .• 257.7210-7216. 1982. 
96. Katada T. and Ui M .• Proc. NatJ. Acad. Sci .• 79. 3129-3133. 
1982. 
97. Smith C.F.C.. Life Sci .• 40,267-274. 1987. 
98. DeLean A.. Stadel J.M .• Lefkowitz RJ .• 1. BioI. Chem .• 255. 
7108-7117, 1980. 
99. Gilman A.G .• Trends Neurosci.. 9.460-461. 1986. 
100. Spain IW. and Coscia CJ .• 1. BioI. Chem .• 262. 8948-8951.1987. 
101. Paton W.D.M. and Zar A.B.. 1. Physiol.. 194. 13-33. 1968. 
102. Lowry O.H.. Rosebrough NJ .• Farr A.L. and Randall RJ .• 1. BioI. 
Chem .• 193.265-275.1951. 
103. Schacterle G.R. and Pollack R.L., Anal. Biochem .• 51. 654-655. 
1973. 
209 
104. Scatchard G., Ann. N. Y. Acad. Sci., 51, 660-672, 1949. 
105. Munson PJ. and Rodbard D., Anal. Biochem., 107, 220-239, 
1980 
106. Hill AV., 1. Physiol., 40, iv-vii, 1910. 
107. Leslie F.M., Pharmacol. Rev., 39, 197-249, 1987. 
108. Cheng Y.-C. and Prusoff W.H., Biochem. Pharmacol., 22, 
3099-3108, 1973. 
109. Arunlakshana O. and Schild H.O., Br. J. Pharmacol., 14,48-58, 
1959. 
110. Robson L.E., Foote R.W., Maurer R. and Kosterlitz H.W., Neurosci., 
12,621-627, 1984. 
Ill. Klee W.A and Nirenberg M., Proc. Natl. Acad. Sci., 71, 
3474-3477,1974. 
112. Traynor J.R., Corbett A.D. and Kosterlitz H.W., Bur. J. Pharmacol. 
137,85-89, 1987. 
113. Bloomfield S.S., Mitchell J., Sinkfield A., Cissell G.B. and Barden T.P., 
IU P H AR 9th I nternat ional Congress of Pharmacology, Abst., 
1737P, 1984. 
114. Nelson E.D., Bloomfield S.S., Barden T.P., Mitchell J., Cissell G.B. and 
Sinkfield A, Curr. Ther. Res. Clin. Exp., 41, 276-289, 1987. 
115. Kent R.S., DeLean A and Lefkowitz R.1., Mol. Pharmacol., 17, 
14-23, 1979. 
116. Paterson S.1., Robson L.E. and Kosterlitz H.W., Br. Med. Bull., 
39,31-36,1983. 
117. Wood M.S. and Traynor J.R., J. Neurochem. 53,173-178, 
1989. 
118. FrostJ.1., Smith AC. and Wagner Jr. H.N., LifeSci., 38,1597-1606, 
1986. 
119. Shaw 1.S., Carroll J.A, Alcock P. and Main RG., Br. 1. Pharmacol., 
96, 986-992, 1989. 
120. Creese I., Prosser T. and Snyder S.H., Life Sci., 23, 495-500, 1978. 
210 
121. Lucas M. and Bockaert J., Mol. PharmacoI., 13,314-329,1977. 
122. U'Prichard D.C. and Snyder S.H., J. BioI. Chem., 253,3444-3452, 
1978. 
123. Fryer R.I., Cook. e., Gilman N.W. and Walser A, Life Sci., 39, 
1947-1957, 1986. 
124. Loew G.H. and Berkowitz D.S., J. Med. Chem., 22, 603-607, 
1979. 
125. Hutchins C.W., Cooper G.K., Purro S. and Rapoport H., J. Med. 
Chem., 24,773-777, 1981. 
126. Hutchins H.W. and Rapoport H., J. Med. Chem., 27, 521-527, 
1984. 
127. Feinberg AP., Creese I. and Snyder S.H., Proc. NatI. Acad. Sci., 
73,4215-4219, 1976. 
128. Tyers M.B., Hayes AG. and Sheehan MJ., NIDA Res. Monogr., 
75, 698, 1986. 
129. Oka T., Negishi K., Suda M., Matsumiya T., Inazu T. and Ueki M., 
Eur. J. PharmacoI., 73, 235-236, 1981. 
130. Howes IF., Villarreal lE., Harris L.S., Essigmann E.M. and 
Cowan A, Drug Alcohol Depend., 14,373-380, 1985. 
131. Sheehan MJ., Hayes AG. and Tyers M.B., Eur. J. PharmacoI., 
130,57-64, 1986. 
132. Corbett AD., Kosterlitz H. W., McKnight AT. and Marcoli M., 
J. PhysioI., 357, 128P, 1984. 
133. Pfeiffer A and Herz A, Biochem. Biophys. Res. Comm., 101, 
38-44, 1981. 
134. Rosenbaum IS., Holford N.H.G., Richards M.L., Aman R.A and 
Sadee W., Mol. PharmacoI., 25,242-248, 1984. 
135. Sadee W., Perry D.C., Rosenbaum 1.S. and Herz A, Eur. J. 
PharmacoI., 81,431-440,1982. 
136. Kurowski M., Rosenbaum 1.S., Perry D.e. and Sadee W., Brain Res., 
249, 345-352, 1982. 
211 
137. Gilman A.G., Ann. Rev. Biochem., 56,615-649, 1987. 
138. Rodbell M., Trends Biochem. Sci., 10,461-464, 1985. 
139. Kosterlitz H.W., Paterson S.J. and Robson L.E., 1. Receptor Res., 
8,363-373, 1988. 
140. Vonvoigtlander P.F., Lahti R.A. and Ludens 1.H., 1. Pharmacol. 
Exp. Ther., 224, 7-12, 1983. 
141. Law P.Y., Horn D.S. and Loh H.H., J. BioI. Chem., 260, 3561-3569, 
1985. 
142. Nock B., Rajpara A., O'Connor L.H. and Cicero TJ., Eur. J. 
Pharmacol., 154,27-34, 1988. 
143. Nock B., Rajpara A., O'Connor L.H. and Cicero TJ., Life. Sci., 
42, 2403, 1988. 
144. Stevens C.W. and Yaksh T.L., 1. Pharmaco1. Exp. Ther., 238, 
833-838, 1986. 
145. Smith A.P. and Lee N.M., Ann. Rev. Pharmaco1. Toxico1., 28, 
123-140, 1988. 
146. Carroll 1.A. and Shaw 1.S., Br. J. Pharmacol., 95, 904P, 1988. 
147. Hurlbut D.E., Evans c.1., Barchas 1.0. and Leslie F.M., Eur. 
J. Pharmaco1., 138,359-366, 1987. 
148. Portoghese P.S., Sultana M. and Takemori A.E., Eur. J. Pharmacol., 
146, 185-186, 1988. 
149. North R.A., Williams 1.T., Surprenant A. and Christie MJ., Proc. 
Natl. Acad. Sci., 84,5487-5491, 1987. 
150. Traynor 1.R., Hayes A.G. and Lawrence A.J., Adv. in the Biosci .• 
75. 109-113. 1989. 
151. Kenakin T.P .• Eur. J. Pharmacol.. 66. 295-306. 1980. 
152. Personal communication. Dr. 1. Shaw. ICI Pharmaceuticals. 
153. Costa T. and Herz A.. Proc.NatI. Acad.Sci .• 86.7321-7325,1989. 
154. Kelly P.D.,RanceM.J.andTraynor 1.R., Neuropeptides, 2, 319-324, 
1982. 
212 
155. Barnard E.A. and Demoliou-Mason C., Br. Med. Bull., 39, 37-45, 
1983. 
156. Wood M.S., Rodriguez F.D. and Traynor lR., Neuropharmaco1., 
28, 1041-1046, 1989. 
157. Cotton R., Kosterlitz RW., Paterson S.1., Ranee M.I and Traynor 
J.R., Br. I. Pharmaco1., 84, 927-932, 1985. 
158. Jones A.K.P., Hume S., Myers R., Manjil L.G. and Cremer lE. 
Br. Opioid con, P 12, 1990. 
159. Dixon D.M. and Traynor IR., I. Neurochem., in press. 
160. Iyengar S., Kim RS. and Wood P.L., Life Sci., 39, 637-644, 
1986. 
161. Clark lA., Liu L., Price M., Hersh B., Ede1son M. and Pasternak 
G.W., I. Pharmaco1. Exp. Ther., 251, 461-468,1989. 
162. Michne W.F., Lewis R.T., Micha1ec S.1., Pierson A.K. and 
Rosenberg FJ., J. Med. Chem., 22, 1158,1979. 
163. Frost J.1., Wagner Jr. RN., Danna1s R.F., Ravert H.T., Links lM., 
Wilson A.A., Burns H.D., Wong D.F., MePherson R.W., 
Rosenbaum A.B., Kuhar M.1. and Snyder S.H., I. Comp. Asst. 
Tom., 9, 231-236, 1985. 
164. Paterson S.1. and Kosterlitz H.W., Br. Opioid Coll., P23, 
1990. 
165. Wood M.S. and Traynor lR., Neuropeptides, 10, 313-320. 
1987. 
213 
All Text and Graphics 
Created 
By 
""<lLe'ERGRAFIX 
vuCCOC;C}, d .. LI 'f -i,-I,,"hgn? ,: f"" "" ..• "~ 
Camputer Graphics and Word Processing 
LAZERGRAFIX 
t46 Bottleacre Lane 
Loughbarough 
Leicestershire 
LEtt tJQ 
TEL: (0509) 267679 

